WO2017030394A1 - Pharmaceutical composition for treating or preventing obesity - Google Patents

Pharmaceutical composition for treating or preventing obesity Download PDF

Info

Publication number
WO2017030394A1
WO2017030394A1 PCT/KR2016/009118 KR2016009118W WO2017030394A1 WO 2017030394 A1 WO2017030394 A1 WO 2017030394A1 KR 2016009118 W KR2016009118 W KR 2016009118W WO 2017030394 A1 WO2017030394 A1 WO 2017030394A1
Authority
WO
WIPO (PCT)
Prior art keywords
cluh
bmper
protein
obesity
agent
Prior art date
Application number
PCT/KR2016/009118
Other languages
French (fr)
Korean (ko)
Inventor
이기호
신현진
정원희
송지영
이은주
함용호
김성섭
홍성희
Original Assignee
한국원자력의학원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국원자력의학원 filed Critical 한국원자력의학원
Publication of WO2017030394A1 publication Critical patent/WO2017030394A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • the present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising an agent for inhibiting the expression or activity of at least one protein of CLUH (Clustered mitochondrial homolog) and BMPER (BMP binding endothelial regulator) protein, or a gene encoding the at least one protein.
  • a pharmaceutical composition for inhibiting or promoting differentiation into adipocytes and a method of treating obesity comprising administering the pharmaceutical composition.
  • screening of an anti-obesity agent or an agent for controlling differentiation into adipocytes comprising the step of measuring the expression or activity of the protein or gene and a composition for diagnosis of obesity comprising an agent for measuring the expression or activity of the protein or gene
  • the present invention relates to a method for diagnosing obesity.
  • the present invention relates to a kit for screening an obesity agent or a differentiation modulator comprising an agent for measuring the expression level of the protein or gene and a kit for assaying the efficacy of an obesity agent or a differentiator. Furthermore, the present invention relates to compositions and kits for detecting markers for the diagnosis of obesity. Furthermore, the present invention relates to a composition and kit for detecting markers capable of measuring differentiation into adipocytes.
  • Obesity is a biological phenomenon caused by the interaction of genetic, metabolic, environmental and behavioral complex factors and is generally recognized as overweight.
  • BMI body mass index
  • Fat stored in fat cells is used as an important energy source in the body.
  • adipocytes increase numerically but also large amounts of triglyceride synthesis by the differentiation of excessive adipocytes are accompanied by morphological changes including the increase of adipocyte size and various gene expression changes.
  • Increasing the size of fat cells is induced by synthesizing and storing surplus energy in the form of triglycerides.
  • the increase in the size of fat cells can be increased by about 20 times in diameter, and as a result, the cell volume is known to increase by several thousand times.
  • the size of the adipocytes is generally controlled by diet, but the process of differentiating new progenitor cells into adipocytes is not effective as dietary control. It is important to adjust.
  • CLUH Clustered mitochondrial homolog
  • mitochondrial protein mRNA to regulate the in vivo synthesis of mitochondria. Only some are known about the involvement of in vivo synthesis (Aurelia De Pauw et al., Am J Pathol. 2009, 175 (3): 927-939, 2009.09). The fact that CLUH is involved in the process of adipocyte differentiation is unknown.
  • BMPER bone morphogenetic protein
  • BMP bone morphogenetic protein
  • the BMPER is known to be involved in tumor growth (J. Heinke et al., Oncogene, 2012, 31, 2919.2930, 2011.10.24) and is known to have a protective effect against atherosclerosis (Xinchun Pi et. al., Arterioscler Thromb Vasc Biol. 2012, 32 (9): 2214.2222, July 5, 2012), the fact that it is involved in the process of adipocyte differentiation is unknown.
  • the present inventors have tried to find a pharmaceutical composition that can prevent or treat obesity, and as a result, it is possible to prevent or treat obesity by inhibiting the expression of CLUH or BMPER, and to determine the expression level of the anti-obesity drug can be screened.
  • the present invention was completed.
  • One object of the present invention is to treat obesity comprising an agent that inhibits the expression or activity of one or more proteins of a clustered mitochondrial homolog (CLUH) and a BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins, or It provides a preventive pharmaceutical composition, and a pharmaceutical composition for controlling differentiation into adipocytes.
  • CLUH clustered mitochondrial homolog
  • BMPER BMP binding endothelial regulator
  • Another object of the present invention is a composition for diagnosing obesity, comprising an agent for measuring the expression level of a clustered mitochondrial homolog (CLUH) or a BMP binding endothelial regulator (BMPER) or a gene encoding the protein, and a diagnostic kit and a fat tax It is to provide a composition capable of measuring differentiation of captivity, and a measurement kit.
  • CLUH clustered mitochondrial homolog
  • BMPER BMP binding endothelial regulator
  • Still another object of the present invention is to provide a diagnostic marker for obesity of CLUH or BMPER protein or gene, and a marker for determining differentiation into adipocytes.
  • Yet another object of the present invention is to provide a method for screening an agent for treating obesity or an agent for differentiation into adipocytes, which comprises measuring the expression level or activity of a CLUH or BMPER protein or a gene encoding the protein.
  • Yet another object of the present invention is to provide a kit for screening an agent for treating obesity or controlling differentiation into adipocytes, the method comprising measuring the expression level of a CLUH or BMPER protein or a gene encoding the protein.
  • the pharmaceutical composition of the present invention can inhibit the differentiation and accumulation of fat into adipocytes, thereby preventing or treating obesity.
  • CLUH Clustered mitochondrial homolog
  • BMPER BMP binding endothelial regulator
  • 1 is a diagram showing the increase in the expression of CLUH during the accumulation of fat and adipocyte differentiation.
  • FIG. 2 is a diagram showing the reduction of fat accumulation and adipocyte differentiation by inhibiting CLUH using CLUH siRNA.
  • FIG. 3 is a diagram showing the increase in the expression of BMPER in the process of fat accumulation and adipocyte differentiation.
  • FIG. 4 is a diagram showing the reduction of fat accumulation and adipocyte differentiation by inhibiting BMPER expression using BMPER siRNA.
  • an aspect of the present invention is an agent that inhibits the expression or activity of at least one protein of CLUH (Clustered mitochondrial homolog) and BMPER (BMP binding endothelial regulator) protein, or the gene encoding the at least one protein It provides a pharmaceutical composition for treating or preventing obesity.
  • the composition may include CLUH, BMPER, or an agent that inhibits the expression or activity of CLUH and BMPER proteins or genes encoding the proteins.
  • CLUH Clustered mitochondrial homolog
  • CLUH Clustered mitochondrial homolog
  • Specific sequencing and protein information of the gene encoding the CLUH can be obtained from a known database such as GeneBank of NCBI (for example, NM_001081158.2, NP_001074627.1.)
  • the CLUH As long as it exhibits the effect of inducing differentiation of fat cells and inducing fat accumulation, homologous proteins or variant proteins thereof may also be included in the scope of CLUH provided by the present invention.
  • the specific base sequence of the gene encoding the CLUH may be SEQ ID NO: 5, but is not limited thereto.
  • BMPER bone morphogenetic protein
  • BMP bone morphogenetic protein
  • the protein is known to inhibit BMP2- and BMP4-dependent osteoblast differentiation and BMP-dependent chondrogenic cell differentiation. Mutations in the gene encoding the protein are known to be associated with severe skeletal disease. Specific base sequence and protein information of the gene encoding the BMPER can be obtained from a known database such as GeneBank of NCBI (for example, NM_028472.2, NP_082748.1).
  • homologous proteins or variant proteins thereof may also be included in the scope of the BMPER provided by the present invention, as long as they exhibit the effect of inducing differentiation of fat cells and inducing fat accumulation.
  • the specific base sequence of the gene encoding the BMPER may be SEQ ID NO: 10, but is not limited thereto.
  • the term "homology" is intended to indicate a degree of similarity to the amino acid sequence of a wild type protein or a base sequence encoding the same, and the amino acid sequence or base sequence of the present invention and Includes sequences having more than one percent identical sequence. Such homology may be determined by visually comparing two sequences, but may be determined using a bioinformatic algorithm that analyzes the degree of homology by arranging the sequences to be compared side by side. Homology between the two amino acid sequences can be expressed as a percentage. Useful automated algorithms are available in the GAP, BESTFIT, FASTA and TFASTA computer software modules of the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, W, USA).
  • Automated alignment algorithms in this module include Needleman & Wunsch and Pearson & Lipman and Smith & Waterman sequence alignment algorithms. Algorithms and homology determinations for other useful arrays are automated in software including FASTP, BLAST, BLAST2, PSIBLAST and CLUSTAL W.
  • the term "agent capable of inhibiting expression or activity” refers to a substance capable of inhibiting the production of a transcript or protein expressed and produced in a gene.
  • the agent includes a transcription factor that binds to a gene and inhibits it at the transcription level; Interfering RNA such as miRNA, siRNA, shRNA, etc., which bind to the transcript that is transcribed and synthesized to degrade the transcript; Compounds which inhibit the expression or inhibit the activity of the CLUH or BMPER, such as low molecular weight compounds; It may be an antibody, aptamer, antagonist, etc. which can bind to the expressed protein, but is not limited thereto.
  • the term "short interfering RNA” refers to double-stranded RNA capable of inducing RNAi that inhibits the activity of a gene.
  • the interference RNA may be miRNA, siRNA, shRNA, etc., which can inhibit the expression of CLUH or BMPER, but the interference RNA may be in any form as long as it inhibits the expression or activity of the CLUH or BMPER gene. It is possible.
  • siRNA obtained by chemical synthesis or biochemical synthesis or in vivo synthesis, or 10 base band or more double stranded RNA in which about 40 bases or more of double stranded RNA is degraded in the body can be used.
  • siRNA that inhibits the expression of CLUH may be siRNA of SEQ ID NO: 3, or siRNA of SEQ ID NO: 4, but is not limited thereto.
  • siRNA that inhibits the expression of BMPER may be siRNA of SEQ ID NO: 8, or siRNA of SEQ ID NO: 9, but is not limited thereto.
  • the interfering RNA is not limited to some of the genes encoding the respective proteins, but specifically about 70%, 75%, 80%, 85%, 90%, 95% or 100% It may be composed of homologous sequences, and RNA or modified variants thereof including double stranded portions may be used.
  • the term “low molecular weight compound” is not limited, and may be included in the present invention as long as it can suppress the expression or inhibit the activity of CLUH or BMPER, and may be a substance derived from nature or a synthesized substance. Specifically, it may be an organic synthetic material or a natural material.
  • the term "antibody” refers to a proteinaceous molecule capable of specifically binding to an antigenic site of a protein or peptide molecule. Such an antibody may be prepared by cloning each gene into an expression vector according to a conventional method. The protein encoded by the marker gene can be obtained and prepared by conventional methods from the obtained protein.
  • the form of the antibody is not particularly limited and, if it is a polyclonal antibody, a monoclonal antibody or antigen-binding, a part thereof may be included in the antibody of the present invention and may include all immunoglobulin antibodies, as well as humanized antibodies. It may also contain a special antibody of.
  • the antibodies include functional fragments of antibody molecules as well as complete forms having two full length light chains and two full length heavy chains.
  • a functional fragment of an antibody molecule means a fragment having at least antigen binding function and may be Fab, F (ab '), F (ab') 2 and Fv.
  • the antibody may be an antibody that can specifically bind to CLUH or BMPER protein.
  • aptamer refers to a nucleic acid molecule having binding activity to a given target molecule.
  • the aptamers may be RNA, DNA, modified nucleic acids, or mixtures thereof, and may be linear or cyclic.
  • the shorter the sequence of nucleotides constituting the aptamer the more chemical synthesis and mass production. It is known to be easier, cost-effective, easy to modify chemical formula, excellent in vivo stability and low toxicity.
  • the aptamer may be interpreted as a means capable of inhibiting the activity of the protein by binding to the CLUH or BMPER protein.
  • the term "antagonist” refers to a molecule capable of directly or indirectly reducing a biological activity of a receptor, and when used with a ligand of a receptor, a molecule capable of reducing the action of the ligand is used. Including but not limited to.
  • the antagonist includes a molecule which inhibits the activity of CLUH or BMEPR protein without limitation, and in particular, the antagonist means a molecule that inhibits activity by binding to CLUH or BMPER protein, but is not limited thereto.
  • the term "obesity" means a condition or disease with excess body fat due to energy imbalance.
  • prevention of the present invention means any action that inhibits or delays the development of obesity by administration of the pharmaceutical composition according to the present invention.
  • the expression of CLUH or BMPER is increased during the differentiation and adipocyte accumulation process to adipocytes It was confirmed that (Figs. 1 and 3).
  • the present inventors can prevent or treat obesity by controlling the expression of CLUH or BMPER into adipocytes and accumulating fat, and furthermore, by measuring its expression level, diagnosing obesity or screening for obesity treatment I could see that.
  • the pharmaceutical composition of the present invention may be prepared in the form of a pharmaceutical composition for treating or preventing obesity, further comprising a suitable carrier, excipient, or diluent commonly used in the manufacture of the pharmaceutical composition, wherein the carrier is an unnatural carrier. (non-naturally occuring carrier).
  • the pharmaceutical composition may be formulated in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be.
  • carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid form forms at least one excipient such as starch, calcium carbonate, sucrose or lactose. (lactose), gelatin, etc. are mixed and prepared.
  • lubricants such as magnesium styrate and talc are also used.
  • Liquid preparations for oral use may include various excipients, such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to water and liquid paraffin, which are commonly used to include suspensions, solutions, emulsions, and syrups. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the content of the formulation included in the pharmaceutical composition of the present invention is not particularly limited, but may be included in an amount of 0.0001 to 50% by weight, more preferably 0.01 to 10% by weight based on the total weight of the final composition.
  • the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount
  • the term "pharmaceutically effective amount" of the present invention is to treat or prevent the disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention
  • Sufficient amount means an effective dose level means the severity of the disease, the activity of the drug, the age, weight, health, sex, sensitivity of the patient to the drug, the time of administration of the composition of the invention used, the route of administration and the rate of excretion
  • the duration of treatment, factors including drugs used in combination or coincidental with the composition of the invention used, and other factors well known in the medical art can be determined.
  • the pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. In consideration of all the above factors, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects.
  • the dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction of the disease, the age, weight, sex, history, or type of substance used as an active ingredient.
  • the pharmaceutical composition of the present invention may be administered to a mammal, including humans, at 10 to 100 mg / kg, more preferably 10 to 30 mg / kg, per day, and the frequency of administration of the composition of the present invention may be
  • the present invention is not limited thereto, but may be administered once to three times a day or several times in divided doses.
  • the present invention provides a method for preventing or treating obesity, comprising administering a pharmaceutical composition for treating or preventing obesity to an individual at risk of developing obesity or obesity.
  • the composition may include CLUH, BMPER, or an agent that inhibits the expression or activity of CLUH and BMPER proteins or genes encoding the proteins.
  • prevention of the present invention is as described above.
  • treatment of the present invention means any action that improves or advantageously changes the condition of obesity by administering the pharmaceutical composition of the present invention.
  • a method for preventing or treating obesity through the administration of a pharmaceutical composition for treating or preventing obesity which may improve or benefit the symptoms of obesity in an obese individual, or suspect an onset of obesity or a risk of developing obesity Obesity can be prevented from developing.
  • the present invention provides a composition for diagnosing obesity, comprising an agent for measuring the expression level of one or more proteins of a clustered mitochondrial homolog (CLUH) and a BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins.
  • CLUH clustered mitochondrial homolog
  • BMPER BMP binding endothelial regulator
  • the composition may include a CLUH, BMPER, or an agent for measuring the expression level of the CLUH and BMPER protein or the gene encoding the protein.
  • CLUH Clustered mitochondrial homolog
  • BMPER BMP binding endothelial regulatr
  • the term “agent capable of measuring the level of a protein or expression level of a gene encoding the protein” specifically refers to an antisense oligonucleotide, primer pair that specifically binds to mRNA of the CLUH or BMPER gene. , But may be selected from the group consisting of probes or antibodies, aptamers, antagonists, and combinations thereof that specifically bind to the CLUH or BMPER protein, but is not limited thereto.
  • the antibodies, aptamers, and antagonists are the same as described above.
  • primer refers to a nucleic acid sequence having a short free 3 'hydroxyl group, which can form complementary templates and base pairs and is the starting point for template strand copying. It refers to a short nucleic acid sequence that functions as. Primers can initiate DNA synthesis in the presence of four different nucleoside triphosphates and reagents for polymerization (ie, DNA polymerase or reverse transcriptase) at appropriate buffers and temperatures. PCR conditions, sense and antisense primer lengths can be modified based on what is known in the art.
  • the primers can be modified, for example methylation, encapsulation, substitution of nucleotides or modifications between nucleotides, for example uncharged linkages such as methyl phosphonate, phosphoester, phosphoroamidate , Carbamate, etc.) or charged linkers (eg, phosphorothioate, phosphorodithioate, etc.).
  • uncharged linkages such as methyl phosphonate, phosphoester, phosphoroamidate , Carbamate, etc.
  • charged linkers eg, phosphorothioate, phosphorodithioate, etc.
  • the 5 'or 3' end of the primer may be labeled with a fluorescent material or the like.
  • the fluorescent material used is not particularly limited, but FAM (6-carboxyfluorescein), HEX (2 ', 4', 5 ', 7',-tetrachloro-6-carboxy-4,7-dichlorofluorescein), NED TM Etc. can be used.
  • primer pairs of the present invention include SEQ ID NOs: 1 and 2; Or it may be a primer having a sequence of SEQ ID NO: 6 and 7, but is not limited thereto.
  • probe refers to a nucleic acid fragment such as RNA or DNA, which may correspond to a short base to several hundred bases, which may achieve specific binding with a gene or mRNA, and includes an oligonucleotide probe, It may be prepared in the form of single stranded DNA probe, double stranded DNA probe, RNA probe, or the like, and may be labeled for easier detection.
  • diagnosis of the present invention refers to confirming the presence or characteristics of a pathological state, and for the purposes of the present invention, may be to confirm whether obesity exists.
  • the CLUH or BMPER protein or a gene encoding the protein of a sample isolated from a normal person and a subject suspected of obesity is measured to determine the CLUH or BMPER protein of the subject suspected of obesity or the same.
  • Obesity can be determined when the expression level of the encoding gene is increased than normal.
  • the normal person means an individual who is not obese.
  • the present invention provides a kit for diagnosing obesity, comprising the composition for diagnosing obesity.
  • the diagnostic composition for obesity may include a CLUH, BMPER, or an agent for measuring the expression level of the CLUH and BMPER protein or the gene encoding the protein.
  • the "kit” of the present invention may further include instructions for describing optimal reaction performance conditions. Instructions include brochures in the form of pamphlets or leaflets, labels affixed to the kit, and instructions on the surface of the package containing the kit. In addition, the guide may include information disclosed or provided through an electronic medium such as the Internet.
  • the kit may be an RT-PCR kit or a DNA analysis (eg, DNA chip) kit, or a protein chip kit.
  • the kit of the present invention may be a kit including essential elements necessary for performing RT-PCR.
  • RT-PCR kits in addition to each primer pair specific for CLUH or BMPER, RT-PCR kits can be used in test tubes or other appropriate containers, reaction buffers (variable in pH and magnesium concentrations), deoxynucleotides (dNTPs), Taq- Enzymes such as polymerase and reverse transcriptase, DNase, RNAse inhibitors, DEPC-water, sterile water, and the like. It may also include primer pairs specific for the gene used as a quantitative control.
  • DNA chip kits are those in which a nucleic acid species is attached in a gridded array to a glass surface that is generally no larger than a flat solid support plate, typically a microscope slide.
  • hybridization between the nucleic acid of the phase and the complementary nucleic acid contained in the solution treated on the surface of the chip (hybridization) is a tool that allows massively parallel analysis.
  • the protein chip kit may be a kit in which one or more antibodies against a marker are arranged at a predetermined position on a substrate and immobilized at a high density.
  • the protein is separated from the sample, and the separated protein is hybridized with the protein chip to form an antigen-antibody complex, which can be read to confirm the presence or expression level of the protein.
  • Obesity can be determined using the obesity diagnostic kit of the present invention by measuring the expression level of CLUH or BMPER protein or a gene encoding the protein of an obese subject in question.
  • the present invention provides a composition for inhibiting adipocyte differentiation, which comprises an agent for inhibiting the expression or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the composition may include CLUH, BMPER, or an agent that inhibits the expression or activity of CLUH and BMPER proteins or genes encoding the proteins.
  • an agent that inhibits the expression or activity of a CLUH or BMPER protein or a gene encoding said protein is as described above.
  • composition for inhibiting adipocyte differentiation of the present invention can suppress differentiation into adipocytes by inhibiting the expression or activity of CLUH or BMPER.
  • the present invention provides a method for diagnosing obesity, comprising measuring the expression level of one or more proteins of the CLUH and BMPER proteins, or a gene encoding the one or more proteins.
  • the diagnostic method of obesity may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
  • the "diagnosis method of obesity" of the present invention CLUH or BMPER of the subjects suspected of obesity by measuring the expression level of CLUH or BMPER protein or the gene encoding the protein, respectively, from samples isolated from normal and suspected obesity Obesity can be determined when the expression level of the protein or gene encoding it is increased than normal.
  • the normal person means an individual who is not obese.
  • Determination of the expression level of a CLUH or BMPER protein or a gene encoding the protein can be performed by antisense oligonucleotides, primer pairs, probes that specifically bind to the mRNA of the CLUH or BMPER gene, or specifically binding to the CLUH or BMPER protein. It may be measured using an antibody, aptamer, antagonist, but is not limited thereto.
  • the term "individual" of the present invention means all animals, including humans, who are likely to develop or develop such obesity.
  • isolated sample of the present invention which is isolated from the individual, including the mRNA of the CLUH or BMPER protein or the gene encoding the protein, in the present invention can measure the expression level of the protein or gene Meaning a sample, the sample is not particularly limited, but may be, for example, isolated tissue or separated cells.
  • a method for treating a CLUH or BMPER gene which comprises: (a) treating a candidate agent for treating obesity; (b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein, in cells treated with the anti-obesity agent candidate in step (a); And (c) when the expression amount or activity measured in step (b) is lower than that of the control cells that did not treat the obesity candidate drug substance, judging the candidate agent for obesity treatment as an obesity agent. It provides a screening method.
  • the screening method of the anti-obesity agent may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
  • the term “therapeutic agent for obesity” refers to a substance that induces inhibition of adipocyte differentiation in an obese individual and has effects such as body fat reduction, fat accumulation inhibition, weight loss, and the like.
  • Nucleic acids, proteins, other extracts or natural products, or compounds, and the like, and specifically, may be, but not limited to, low molecular weight compounds, organic synthetic materials, natural materials, microRNA, siRNA, shRNA, antibodies, aptamers, etc. .
  • the term “substance candidate for obesity” refers to a substance capable of becoming an anti-obesity agent as described above, and is estimated to have a possibility of treating obesity or randomly selected according to a conventional selection method.
  • Individual nucleic acids, proteins, other extracts or natural products, or compounds, and the like, and specifically, may be low molecular weight compounds, organic compounds, natural materials, microRNAs, siRNAs, shRNAs, antibodies, aptamers, and the like. It doesn't work.
  • the measurement of the expression level or activity of the protein or the gene encoding the protein may be to measure the expression level of the CLUH or BMPER protein or the mRNA of the gene.
  • measuring the mRNA expression level of the CLUH or BMPER gene may use antisense oligonucleotides, primer pairs, probes or a combination thereof that specifically binds to the mRNA of the gene, which may include reverse transcriptase polymerase reaction, Competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting and DNA microarray chip can be performed using an assay selected from the group consisting of, but not limited to.
  • measuring the expression level of the CLUH or BMPER protein may use an antibody, aptamer, antagonist or a combination thereof that specifically binds to the protein, which may be Western blotting, ELISA, radioimmunoassay, radioimmunoassay.
  • control refers to a cell or tissue expressing CLUH or BMPER that has not been treated with an anti-obesity candidate, and that is in a parallel relationship with the group treated with the candidate.
  • screening method of the obesity treatment agent by identifying the expression of CLUH and BMPER involved in the process of differentiation into adipocytes, the activity and expression of the CLUH and BMPER and the control cells not treated with the candidate drug substance It is designed in a way of comparison. Measuring the expression level of the gene of the present invention or the level of the protein encoded by the gene in a cell in the absence of a candidate agent capable of preventing or treating obesity, and also in the presence of the candidate agent After comparing the two by measuring the expression level or the level of the protein encoded by the gene, the expression level of the gene of the present invention when the candidate substance is present or the level of the protein encoded by the gene is absent of the candidate substance. Substances that decrease below levels can be predicted as agents for the prevention or treatment of obesity.
  • Substances obtained by this screening method will act as a leading compound in the future development of a prophylactic or therapeutic agent for obesity, and its structure may be modified so that the leading substance can exhibit an inhibitory effect on CLUH or BMPER or a gene encoding the same.
  • new obesity prophylaxis or treatments can be developed, and these substances can have a partial or complete inhibitory effect on CLUH or BMPER or genes encoding them, thereby preventing or treating obesity-related diseases.
  • the present invention provides a therapeutic agent for obesity comprising an agent for measuring the expression level of one or more proteins of the clustered mitochondrial homolog (CLUH) and the BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins.
  • kits for screening comprising an agent for measuring the expression level of one or more proteins of the clustered mitochondrial homolog (CLUH) and the BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins.
  • the kit for screening an obesity agent may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the protein.
  • an obesity therapeutic agent can be selected from an obesity therapeutic candidate.
  • the agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein and the kit are as described above.
  • the present invention provides a kit for assaying efficacy of an obesity therapeutic agent comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the kit for assaying efficacy of the anti-obesity agent may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the protein.
  • Agents and kits for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein in the present invention are as described above.
  • Effectiveacy assay kit for the treatment of obesity agent includes an agent for measuring the expression level of the protein or the gene encoding the protein, CLUH or BMPER protein in cells expressing CLUH or BMPER treated with the anti-obesity agent Or it may be a kit capable of measuring the expression level of the gene. The lower the expression level of CLUH or BMPER measured above can be assayed as an effective obesity treatment.
  • “Efficacy Assay Kit for Obesity Therapeutics” of the present invention includes an agent for measuring the expression level of the protein or the gene encoding the protein, and the CLUH or BMPER protein in cells expressing CLUH or BMPER treated with the anti-obesity agent Or it may be a kit capable of measuring the expression level of the gene. The lower the expression level of the CLUH or BMPER can be assayed as an effective obesity treatment.
  • the present invention provides a method for treating a cell comprising: (a) treating a candidate adipocyte differentiation candidate with a cell expressing a CLUH or BMPER gene; (b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein in cells treated with the adipocyte differentiation promoter candidate in step (a); And (c) determining the adipocyte differentiation candidate as an adipocyte differentiation promoter when the amount of expression or activity measured in step (b) is lower than that of the control cells not treated with the adipocyte differentiation candidate. It provides a method for screening adipocyte differentiation promoter comprising a.
  • the screening method of the adipocyte differentiation promoter may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • the term “fat cell differentiation regulator” refers to any substance capable of promoting or inhibiting differentiation into adipocytes (nucleic acid, protein, other extract or natural product, or compound, etc.), and specifically, the differentiation regulator is MLPH. Induced over-expression or inhibiting expression can promote or inhibit differentiation into adipocytes, or any substance that can cause a significant change in the amount of MLPH expression in the process of promoting or inhibiting differentiation into adipocytes. do. "Fat cell differentiation promoter” and “fat cell differentiation inhibitor” are included in “fat cell differentiation regulator”.
  • the term "dipose cell differentiation promoter candidate” is a single nucleic acid, protein, other extract or natural product presumed to have the potential to promote adipocyte differentiation according to a conventional selection method or randomly selected; Or a compound, and the like, and specifically, may be a low molecular compound, an organic synthetic material, a natural material, a microRNA, siRNA, shRNA, an antibody, aptamer, and the like, but is not limited thereto.
  • screening method of adipocyte differentiation promoter confirms that expression of CLUH or BMPER is involved in the process of differentiating into adipocytes, thereby preventing the activity and expression of CLUH or BMPER to treat adipocyte differentiation candidate candidates. It was designed in a way that compares with control cells.
  • Measuring the expression level of the gene of the present invention or the level of the protein encoded by the gene in the cell in the absence of a candidate agent capable of promoting the differentiation of adipocytes, and also in the presence of the candidate agent After comparing the two by measuring the expression level of the gene or the level of the protein encoded by the gene, the expression level of the gene of the present invention when the candidate substance is present or the level of the protein encoded by the gene is determined as the candidate substance. Substances that increase above the level in the absence of can be predicted as adipocyte differentiation promoters.
  • the present invention provides a method for treating a cell comprising: (a) treating an adipocyte differentiation inhibitor candidate to a cell expressing a CLUH or BMPER gene; (b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein in cells treated with the adipocyte differentiation inhibitor candidate in step (a); And (c) determining the adipocyte differentiation inhibitor candidate as an adipocyte differentiation inhibitor when the amount of expression or activity measured in step (b) is lower than that of the control cells not treated with the adipocyte differentiation inhibitor candidate. It provides a method for screening an adipocyte differentiation inhibitor comprising a.
  • the screening method of the adipocyte differentiation inhibitor may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
  • the term “dipotent differentiation inhibitor candidate” refers to individual nucleic acids, proteins, other extracts or natural products presumed to have the possibility of inhibiting adipocyte differentiation according to a conventional selection method or randomly selected; Or a compound, and the like, and specifically, may be a low molecular compound, an organic synthetic material, a natural material, a microRNA, siRNA, shRNA, an antibody, aptamer, and the like, but is not limited thereto.
  • screening method of adipocyte differentiation inhibitor confirms that expression of CLUH or BMPER is involved in adipocyte differentiation, thereby not treating the adipocyte differentiation inhibitor candidates with the activity and expression of CLUH or BMPER. It was designed in a way that compares with control cells.
  • Measuring the expression level of the gene of the present invention or the level of the protein encoded by the gene in the cell in the absence of a candidate substance capable of inhibiting the differentiation of adipocytes, and also in the presence of the candidate substance After comparing the two by measuring the expression level of the gene or the level of the protein encoded by the gene, the expression level of the gene of the present invention when the candidate substance is present or the level of the protein encoded by the gene is determined as the candidate substance. Substances that decrease below levels in the absence of can be predicted as adipocyte differentiation inhibitors.
  • the material obtained by this screening method can be used as an inhibitor of adipocyte differentiation, and especially can be used for the prevention or treatment of obesity.
  • the present invention provides a kit for screening an adipocyte differentiation promoter comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the kit for screening the adipocyte differentiation promoter may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • the fat cell differentiation promoter can be selected from the adipocyte candidates for adipocyte differentiation using the kit for screening the adipocyte differentiation promoter of this invention.
  • the "agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein” and the “kit” are as described above.
  • the present invention provides a kit for screening an adipocyte differentiation inhibitor comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the kit for screening the adipocyte differentiation inhibitor may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • the kit for screening an adipocyte differentiation inhibitor of the present invention can be used to select an adipocyte differentiation inhibitor from a candidate adipocyte differentiation inhibitor.
  • the "agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein” and the “kit” are as described above.
  • the present invention provides a kit for assaying the efficacy of an adipocyte differentiation promoter comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the kit for assaying efficacy of the adipocyte differentiation promoter may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • Effectiveacy assay kit for adipocyte differentiation promoter includes an agent for measuring the expression level of the protein or the gene encoding the protein, in the cells expressing CLUH or BMPER treated adipocyte differentiation promoter It may be a kit capable of measuring the expression level of the CLUH or BMPER protein or the gene. The higher the expression level of CLUH or BMPER measured can be assayed as an effective adipocyte differentiation promoter. Such an efficacy assay kit can be effectively used for verifying the titer of adipocyte differentiation promoter in a general adipocyte differentiation process.
  • the present invention provides a kit for assaying the efficacy of an adipocyte differentiation inhibitor comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the kit for assaying efficacy of the adipocyte differentiation inhibitor may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • Effectiveacy assay kit for adipocyte differentiation inhibitor includes an agent for measuring the expression level of the protein or the gene encoding the protein, in the cells expressing CLUH or BMPER treated adipocyte differentiation inhibitor It may be a kit capable of measuring the expression level of the CLUH or BMPER protein or the gene. The lower the expression level of CLUH or BMPER measured above can be assayed as an effective adipocyte differentiation inhibitor. Such an efficacy assay kit can be effectively used for verifying the titer of adipocyte differentiation inhibitor in general adipocyte differentiation process.
  • the present invention provides a composition for detecting a marker for diagnosing obesity, comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the marker detection composition for diagnosing obesity may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
  • the agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein is as described above.
  • the term “marker for diagnosing obesity” may refer to an organic biomolecule that exhibits a significant difference in expression in normal individuals and obese individuals.
  • the marker detection composition for diagnosing obesity of the present invention the level of expression equal to or higher than that of CLUH or BMPER, and for the diagnosis of obesity, the expression level in the non-obese and obese individuals shows a significant difference Markers can be detected.
  • the present invention provides a marker detection kit for diagnosing obesity, comprising a composition for detecting markers for diagnosing obesity.
  • the marker detection composition for diagnosing obesity may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
  • the term “agent for measuring the expression level of a CLUH or BMPER protein or a gene encoding the protein”, “a marker for diagnosing obesity”, “a composition for detecting a marker for diagnosing obesity”, and a kit are described above. As shown.
  • the marker detection kit for diagnosing obesity of the present invention it is possible to detect a marker for diagnosing obesity, which shows a significant difference in expression level than in a control sample.
  • the present invention provides a use of the pharmaceutical composition in the manufacture of a medicament for preventing or treating obesity.
  • the present invention provides the use of a diagnostic marker for obesity of a CLUH or BMPER protein or gene.
  • the present invention provides a composition for promoting adipocyte differentiation comprising an agent for overexpressing one or more proteins of CLUH and BMPER proteins, or a gene encoding the one or more proteins.
  • an agent that overexpresses one or more proteins of CLUH and BMPER protein, or a gene encoding the one or more proteins increases the expression level of CLUH, BMPER or both CLUH and BMPER, thereby promoting differentiation into adipocytes.
  • Any material that can be promoted is not limited, and may be nucleic acids, proteins, other extracts or natural products, or compounds, and specifically, may be low molecular weight compounds, organic synthetic materials, natural materials, and the like. It doesn't work.
  • composition for promoting adipocyte differentiation of the present invention may promote differentiation into adipocytes through overexpression of CLUH or BMPER.
  • the present invention provides a composition for detecting a diagnostic marker for differentiation into adipocytes, which comprises an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • composition for detecting a diagnostic marker for differentiation into adipocytes may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • agent for measuring the expression level of one or more proteins of CLUH and BMPER proteins, or genes encoding said one or more proteins are as described above.
  • differentiation diagnostic marker to adipocytes refers to an organic biomolecule showing a significant difference in expression according to the process of differentiation of adipocytes.
  • composition for detecting a diagnostic marker for differentiation into adipocytes of the present invention can detect organic biomolecules having a difference in expression level at a level equivalent to or higher than that of CLUH or BMPER during the differentiation into adipocytes.
  • the present invention provides a kit for diagnosing differentiation into adipocytes, which comprises an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  • the diagnostic kit for differentiation into adipocytes may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
  • agent for measuring the expression level of one or more proteins of CLUH and BMPER proteins, or genes encoding said one or more proteins are as described above.
  • the diagnostic kit for differentiation into adipocytes of the present invention can measure and diagnose the process of differentiation into adipocytes by measuring the amount of CLUH or BMPER expression.
  • Example 1 Confirmation of the relationship between the clustered mitochondrial homolog (CLUH) expression and adipocyte differentiation
  • 3T3-L1 is a mouse embryonic fibroblast cell line and is mainly used for metabolic disease and obesity research models.
  • Cell lines purchased from ATCC were used by culturing in DMEM (Dulbecco's modified Eagle's medium) including Bovine Calf serum (BCS).
  • DMEM Dulbecco's modified Eagle's medium
  • BCS Bovine Calf serum
  • 3T3-L1 0.8 ⁇ 10 5 cells were seeded in a 35 mm dish to make day 0 when 5 days had passed.
  • differentiation cocktail IBMX 0.5 mM, insulin 10 ug / mL, dexamethson 1uM
  • DMEM Dulbecco's modified Eagle's medium
  • FBS Fetal bovine serum
  • Complementary DNA cDNA was also synthesized using the iScript TM cDNA Synthesis Kit (Biorad, USA), and reverse transcriptase-polymerase chain reaction (RT-PCR) using Maxime PCR PreMix kit (i-StarTaq; Intron Biotechnology). was performed. Primers used for RT-PCR are as follows.
  • the cells were fixed with 3.7% formaldehyde and then incubated with 60% isopropanol for 5 minutes. Thereafter, cell suction was performed and the dish was completely dried. Oil Red and water were diluted 3: 2 and stained with cells. After 1 hour, the cells were washed 2-3 times with water.
  • the 3T3-L1 cell line was used to induce differentiation into adipocytes, and it was confirmed that expression of the CLUH gene of the present invention was increased in the course of differentiation into adipocytes. As disclosed in A of FIG. 1, it was confirmed that the expression of CLUH was increased from the second day of differentiation.
  • siRNA was produced.
  • siCLUH # 1 GCTTCAATCCTGACATCTT SEQ ID NO: 3
  • siCLUH # 3 GGGCATCATTGGCAATGAT SEQ ID NO: 4
  • transfection 100 nM siRNA using Lipofectamine RNAi MAX reagent (Invitrogen, CA) and Opti-MEM (Invitrogen, CA) was performed. transfection) was performed, and from the next day, 3T3-L1 cells were induced to differentiate into adipocytes using a differentiation cocktail (IBMX 0.5 mM, insulin 10 ug / mL, dexamethasone) 1 uM. Insulin treatment every 2 days.
  • a differentiation cocktail IBMX 0.5 mM, insulin 10 ug / mL, dexamethasone
  • the anti-obesity agent can be screened by inhibiting the expression of the CLUH gene to prevent or treat obesity, or by measuring its expression level.
  • BMPER BMP binding endothelial regulator
  • 3T3-L1 is a mouse embryonic fibroblast cell line and is mainly used for metabolic disease and obesity research models.
  • Cell lines purchased from ATCC were used by culturing in DMEM (Dulbecco's modified Eagle's medium) including Bovine Calf serum (BCS).
  • DMEM Dulbecco's modified Eagle's medium
  • BCS Bovine Calf serum
  • 3T3-L1 0.8 ⁇ 10 5 cells were seeded in a 35 mm dish to make day 0 when 5 days had passed.
  • differentiation cocktail IBMX 0.5 mM, insulin 10 ug / mL, dexamethson 1uM
  • DMEM Dulbecco's modified Eagle's medium
  • FBS Fetal bovine serum
  • Complementary DNA cDNA was also synthesized using the iScript TM cDNA Synthesis Kit (Biorad, USA), and reverse transcriptase-polymerase chain reaction (RT-PCR) using Maxime PCR PreMix kit (i-StarTaq; Intron Biotechnology). was performed. Primers used for RT-PCR are as follows.
  • the cells were fixed with 3.7% formaldehyde and then incubated with 60% isopropanol for 5 minutes. Thereafter, cell suction was performed and the dish was completely dried. Oil Red and water were diluted 3: 2 and stained with cells. After 1 hour, the cells were washed 2-3 times with water.
  • the 3T3-L1 cell line was used to induce differentiation into adipocytes, and it was confirmed that expression of the BMPER gene of the present invention was increased in the course of differentiation into adipocytes. As disclosed in FIG. 3A, it was confirmed that the expression of BMPER was increased from the second day of differentiation.
  • BMPER is involved in the process of differentiating into adipocytes, and furthermore, to determine whether or not it can suppress the production of fat by inhibiting the BMPER.
  • siRNA was produced.
  • SiBMPER # 1 SEQ ID NO: 8
  • siBMPER # 3 SEQ ID NO: 9
  • siRNAs of BMPER were made to order and control siRNA (si-Con, SEQ ID NO: 19) was purchased and used (Mbiotech, South Korea, Seoul). .
  • siBMPER # 1 GCATAATGTGTGTGTGTTT SEQ ID NO: 8 siBMPER # 3 GCACAGTATGCACTTGCAA SEQ ID NO: 9
  • transfection 100 nM siRNA using Lipofectamine RNAi MAX reagent (Invitrogen, CA) and Opti-MEM (Invitrogen, CA) was performed. transfection) and the following day was induced to differentiate 3T3-L1 cells into adipocytes using a differentiation cocktail (IBMX 0.5 mM, insulin 10 ug / mL, dexamethasone (1uM)). . Insulin treatment every 2 days.
  • a differentiation cocktail IBMX 0.5 mM, insulin 10 ug / mL, dexamethasone (1uM)
  • BMPER Gene expression of BMPER was measured by RT-PCR during differentiation of 3T3-L1 cells treated with siBMPER # 1 and siBMPER # 3, si-Con, si-Con, siRNA of BMPER. As a result, it was confirmed that the expression of BMPER was inhibited on the third day of differentiation, and the expression of PPAR gamma, a positive marker of differentiation, was also reduced. In addition, it was confirmed that the expression of Id-1, a downstream molecule of BMPER, was also reduced (FIG. 4A).
  • the anti-obesity agent can be screened by inhibiting the expression of the BMPER gene to prevent or treat obesity, or by measuring its expression level.
  • the present inventors have found that CLUH and BMPER are involved in fat accumulation and differentiation into adipocytes from the above examples, and tried to determine whether human cells perform the same function.
  • CLUH and BMPER were confirmed by real time PCR by inducing adipose differentiation in various cells (3T3L1, C3H10T1 / 2, Messenchymal stem cells), including 3T3-L1 cells used in the above examples.
  • Primer sequences of CLUH and BMPER were as follows.
  • RNA sequence is as follows. mRPL13A (Forward 5'-CCTGCTGCTCTCAAGGTTGTT-3 ', SEQ ID NO: 15; Reverse 5'-CGATAGTGCATCTTGGCCTTT-3', SEQ ID NO: 16), ⁇ -actin (Forward 5'-GCACCACACCTTCTACAATGA-3 ', SEQ ID NO: 17; Reverse 5'- TAGCACAGCCTGGATAGCAAC-3 ', SEQ ID NO: 18).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

A clustered mitochondrial homolog (CLUH) or a BMP binding endothelia regulator (BMPER) according to the present invention is involved in differentiation into adipocytes and fat accumulation. Thus, by inhibiting the CLUH or the BMPER, differentiation into adipocytes can be inhibited and obesity can be treated or prevented. Also, by measuring the level of expression of the CLUH or the BMPER, obesity can be diagnosed and screening of an obesity treating agent or a control agent for differentiation into adipocytes is enabled.

Description

비만 치료 또는 예방용 약학 조성물Pharmaceutical composition for the treatment or prevention of obesity
본 발명은 CLUH (Clustered mitochondrial homolog) 및 BMPER (BMP binding endothelial regulator) 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 비만 치료 또는 예방용 약학 조성물 및 지방세포로의 분화를 억제하거나 촉진시키는 약학 조성물 및 상기 약학 조성물을 투여하는 단계를 포함하는 비만의 치료 방법에 관한 것이다. 또한, 상기 단백질 또는 상기 유전자의 발현량 또는 활성을 측정하는 제제를 포함하는 비만 진단용 조성물 및 상기 단백질 또는 상기 유전자의 발현량 또는 활성을 측정하는 단계를 포함하는 비만 치료제 또는 지방세포로의 분화 조절제의 스크리닝 방법, 비만의 진단 방법에 관한 것이다. 더 나아가, 상기 단백질 또는 상기 유전자의 발현수준을 측정하는 제제를 포함하는 비만 치료제 또는 분화 조절제의 스크리닝용 키트 및 비만 치료제 또는 분화 조절제의 효능 검정용 키트에 관한 것이다. 더 나아가, 비만 진단을 위한 마커 검출용 조성물 및 키트에 관한 것이다. 더 나아가, 지방세포로의 분화를 측정할 수 있는 마커 검출용 조성물 및 키트에 관한 것이다.The present invention relates to a pharmaceutical composition for treating or preventing obesity, comprising an agent for inhibiting the expression or activity of at least one protein of CLUH (Clustered mitochondrial homolog) and BMPER (BMP binding endothelial regulator) protein, or a gene encoding the at least one protein. And a pharmaceutical composition for inhibiting or promoting differentiation into adipocytes and a method of treating obesity comprising administering the pharmaceutical composition. In addition, screening of an anti-obesity agent or an agent for controlling differentiation into adipocytes, comprising the step of measuring the expression or activity of the protein or gene and a composition for diagnosis of obesity comprising an agent for measuring the expression or activity of the protein or gene The present invention relates to a method for diagnosing obesity. Furthermore, the present invention relates to a kit for screening an obesity agent or a differentiation modulator comprising an agent for measuring the expression level of the protein or gene and a kit for assaying the efficacy of an obesity agent or a differentiator. Furthermore, the present invention relates to compositions and kits for detecting markers for the diagnosis of obesity. Furthermore, the present invention relates to a composition and kit for detecting markers capable of measuring differentiation into adipocytes.
비만은 유전적, 대사적, 환경적, 그리고 행동학적인 복잡한 요인의 상호작용에 의해 발생하는 생물학적 현상으로서, 일반적으로 체중과다로 인식되고 있다. 의학적으로는 BMI(body mass index)가 30 이상(즉, 표준체중의 30% 이상)인 경우이거나 BMI가 27 이상인 경우 비만으로 분류하는데, 현대인들은 서구화된 식단과 적은 운동량으로 인하여 과체중 및 비만이 증가하고 있다. Obesity is a biological phenomenon caused by the interaction of genetic, metabolic, environmental and behavioral complex factors and is generally recognized as overweight. Medically, people with a body mass index (BMI) of 30 or more (i.e., 30% or more of the standard body weight) or BMI of 27 or more are classified as obesity. Modern people have an increase in overweight and obesity due to a westernized diet and low exercise. Doing.
국제보건기구(World Health Organisation, WHO)에 따르면, 전 세계적으로 10억 이상의 성인이 과체중이고, 그 중 적어도 300만 명 이상이 임상적으로 비만이며, 매년 25,000명 이상이 과체중과 관련된 질환에 의해 사망하는 것으로 보고되었다. 특히 비만은 고혈압, 제2형 당뇨병, 암, 담낭질환, 고지혈증, 동맥경화 등과 같은 각종 성인병을 일으키는 중요한 요인으로 알려져 있다. 비만의 원인을 유전적 원인으로만 보기는 어려우며, 에너지 균형을 파괴하는 유전적, 환경적 복합 요인이 비만의 중요 원인라는 인식이 확산되고 있다.According to the World Health Organization (WHO), over 1 billion adults worldwide are overweight, at least 3 million of them are clinically obese, and more than 25,000 die each year from diseases associated with overweight. Has been reported. In particular, obesity is known to be an important factor causing various adult diseases such as hypertension, type 2 diabetes, cancer, gallbladder disease, hyperlipidemia, arteriosclerosis. It is hard to see the cause of obesity as a genetic cause, and there is a growing awareness that the genetic and environmental complex factors that destroy energy balance are important causes of obesity.
지방세포에 저장된 지방은 체내의 중요한 에너지원으로 사용된다. 그러나, 비만이 진행됨에 따라서 지방세포는 수적으로 증가할 뿐만 아니라 과다한 지방세포의 분화에 의한 다량의 중성지방 합성은 지방세포의 크기 증가를 포함한 형태적 변화와 여러 유전자 발현의 변화를 동반한다. 지방세포의 크기 증가는 잉여 에너지를 중성지방의 형태로 합성 및 저장함으로써 유도된다. 한편, 지방의 저장에 따라 지방세포의 크기 증가는 그 직경이 약 20배까지 늘어날 수 있으며 그 결과 세포 용적은 수천 배까지 증가되는 것으로 알려져 있다. 이러한, 지방세포의 크기는 일반적으로 식사 조절로 가능하지만 새로운 전구지방세포가 지방세포로 분화되는 과정은 식사조절로는 효과가 없기 때문에 비만의 근본적 치료 또는 억제를 제어하기 위해서는 지방세포의 분화과정을 조절하는 것이 중요하다.  Fat stored in fat cells is used as an important energy source in the body. However, as obesity progresses, not only does adipocytes increase numerically but also large amounts of triglyceride synthesis by the differentiation of excessive adipocytes are accompanied by morphological changes including the increase of adipocyte size and various gene expression changes. Increasing the size of fat cells is induced by synthesizing and storing surplus energy in the form of triglycerides. On the other hand, with the storage of fat, the increase in the size of fat cells can be increased by about 20 times in diameter, and as a result, the cell volume is known to increase by several thousand times. The size of the adipocytes is generally controlled by diet, but the process of differentiating new progenitor cells into adipocytes is not effective as dietary control. It is important to adjust.
한편, CLUH (Clustered mitochondrial homolog)은 미토콘드리아 관련 유전자로 알려져 있으나, 그 기능에 관해서는 구체적으로 알려진 바 없다. 단지, 미토콘드리아 단백질의 mRNA와 결합하여 미토콘드리아의 생체 내 합성을 조절하며(Jie Gao et al., J. Cell Biol. Vol. 2014, 207, No. 2, 213-223, 2014.10.27), 미토콘드리아의 생체 내 합성의 관련성에 관해 일부 알려져 있을 뿐이다 (Aurelia De Pauw et al., Am J Pathol.2009, 175(3):927-939, 2009.09). CLUH가 지방세포 분화 과정에 관여하는 사실은 전혀 알려진 바 없다.On the other hand, CLUH (Clustered mitochondrial homolog) is known as a mitochondrial related gene, but its function is not specifically known. Only by binding to mitochondrial protein mRNA to regulate the in vivo synthesis of mitochondria (Jie Gao et al., J. Cell Biol. Vol. 2014, 207, No. 2, 213-223, 2014.10.27) Only some are known about the involvement of in vivo synthesis (Aurelia De Pauw et al., Am J Pathol. 2009, 175 (3): 927-939, 2009.09). The fact that CLUH is involved in the process of adipocyte differentiation is unknown.
또한, BMPER(BMP binding endothelial regulator)은 뼈 형성 단백질 (bone morphogenetic protein, BMP)과 결합하여 이의 기능을 억제한다. 상기 BMPER은 종양 성장에 관여하고 있다고 알려져 있고(J. Heinke et al., Oncogene,2012,31, 2919.2930, 2011.10.24), 죽상동맥경화증 (atherosclerosis)에 대해서 보호 효과가 있다고 알려져 있으나 (Xinchun Pi et al., Arterioscler Thromb Vasc Biol. 2012, 32(9):2214.2222, 2012. 7. 5), 지방세포 분화 과정에 관여하는 사실은 전혀 알려진 바 없다.In addition, BMPER (BMP binding endothelial regulator) binds to bone morphogenetic protein (BMP) and inhibits its function. The BMPER is known to be involved in tumor growth (J. Heinke et al., Oncogene, 2012, 31, 2919.2930, 2011.10.24) and is known to have a protective effect against atherosclerosis (Xinchun Pi et. al., Arterioscler Thromb Vasc Biol. 2012, 32 (9): 2214.2222, July 5, 2012), the fact that it is involved in the process of adipocyte differentiation is unknown.
본 발명자들은 비만을 예방 또는 치료할 수 있는 약학 조성물을 찾기 위해 노력한 결과, CLUH 또는 BMPER의 발현을 억제하여 비만을 예방 또는 치료 할 수 있으며, 이의 발현 수준을 측정하여 비만 치료제를 스크리닝 할 수 있음을 확인하여 본 발명을 완성하였다.The present inventors have tried to find a pharmaceutical composition that can prevent or treat obesity, and as a result, it is possible to prevent or treat obesity by inhibiting the expression of CLUH or BMPER, and to determine the expression level of the anti-obesity drug can be screened. The present invention was completed.
본 발명의 하나의 목적은 CLUH (Clustered mitochondrial homolog) 및 BMPER (BMP binding endothelial regulator) 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 비만 치료 또는 예방용 약학 조성물, 그리고 지방세포로의 분화를 조절하는 약학 조성물을 제공하는 것이다.One object of the present invention is to treat obesity comprising an agent that inhibits the expression or activity of one or more proteins of a clustered mitochondrial homolog (CLUH) and a BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins, or It provides a preventive pharmaceutical composition, and a pharmaceutical composition for controlling differentiation into adipocytes.
본 발명의 다른 하나의 목적은 CLUH (Clustered mitochondrial homolog) 또는 BMPER (BMP binding endothelial regulator) 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 수준을 측정하는 제제를 포함하는, 비만 진단용 조성물, 및 진단키트 및 지방세포로의 분화를 측정할 수 있는 조성물, 및 측정 키트를 제공하는 것이다.Another object of the present invention is a composition for diagnosing obesity, comprising an agent for measuring the expression level of a clustered mitochondrial homolog (CLUH) or a BMP binding endothelial regulator (BMPER) or a gene encoding the protein, and a diagnostic kit and a fat tax It is to provide a composition capable of measuring differentiation of captivity, and a measurement kit.
본 발명의 또 다른 하나의 목적은 CLUH 또는 BMPER 단백질 또는 유전자의 비만 진단 마커 용도 및 지방세포로의 분화를 판단할 수 있는 마커 용도를 제공하는 것이다.Still another object of the present invention is to provide a diagnostic marker for obesity of CLUH or BMPER protein or gene, and a marker for determining differentiation into adipocytes.
본 발명의 또 다른 하나의 목적은 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 단계를 포함하는 비만 진단 방법 및 지방세포로의 분화 판단 방법을 제공하는 것이다.It is yet another object of the present invention to provide a method for diagnosing obesity and determining differentiation into adipocytes, the method comprising measuring expression levels of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein. will be.
본 발명의 또 다른 하나의 목적은 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계를 포함하는 비만 치료제 또는 지방세포로의 분화 조절제의 스크리닝 방법을 제공하는 것이다.Yet another object of the present invention is to provide a method for screening an agent for treating obesity or an agent for differentiation into adipocytes, which comprises measuring the expression level or activity of a CLUH or BMPER protein or a gene encoding the protein.
본 발명의 또 다른 하나의 목적은 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 단계를 포함하는 비만 치료제 또는 지방세포로의 분화 조절제의 스크리닝용 키트를 제공하는 것이다.Yet another object of the present invention is to provide a kit for screening an agent for treating obesity or controlling differentiation into adipocytes, the method comprising measuring the expression level of a CLUH or BMPER protein or a gene encoding the protein.
본 발명의 또 다른 하나의 목적은 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 비만 치료제 또는 지방세포로의 분화를 측정할 수 있는 효능 검정용 키트를 제공하는 것이다.It is another object of the present invention to provide an efficacy assay kit capable of measuring differentiation into an anti-obesity agent or adipocyte, including a CLUH or BMPER protein or an agent for measuring the expression level of the gene encoding the protein. .
본 발명의 또 다른 하나의 목적은 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 비만 진단 및 지방세포로의 분화 측정을 위한 마커 검출용 조성물 및 키트를 제공하는 것이다.It is another object of the present invention to provide a composition and kit for detecting markers for the diagnosis of obesity and the differentiation into adipocytes, including the CLUH or BMPER protein or an agent for measuring the expression level of the gene encoding the protein. .
본 발명의 약학 조성물은 지방세포로 분화와 지방의 축적을 억제하여, 비만을 예방 또는 치료할 수 있다. 또한, 본 발명에 의하면 CLUH (Clustered mitochondrial homolog) 또는 BMPER (BMP binding endothelial regulator)의 발현 수준을 측정하여 비만 치료제, 및 지방세포의 분화 조절제를 스크리닝 할 수 있고, 기존의 비만 치료제 및 지방세포 분화 조절제 효능을 효과적으로 검정할 수 있다.The pharmaceutical composition of the present invention can inhibit the differentiation and accumulation of fat into adipocytes, thereby preventing or treating obesity. In addition, according to the present invention, by measuring the expression level of CLUH (Clustered mitochondrial homolog) or BMPER (BMP binding endothelial regulator) can be screened for the treatment of obesity, and differentiation regulators of adipocytes, and existing obesity and adipocyte differentiation regulators Efficacy can be effectively tested.
도 1은 지방의 축적 및 지방세포 분화 과정에서 CLUH의 발현이 증가하는 것을 나타낸 도이다.1 is a diagram showing the increase in the expression of CLUH during the accumulation of fat and adipocyte differentiation.
도 2는 CLUH siRNA를 이용하여, CLUH을 억제하여 지방의 축적 및 지방세포 분화를 감소시키는 것을 나타낸 도이다.2 is a diagram showing the reduction of fat accumulation and adipocyte differentiation by inhibiting CLUH using CLUH siRNA.
도 3은 지방의 축적 및 지방세포 분화 과정에서 BMPER의 발현이 증가하는 것을 나타낸 도이다.3 is a diagram showing the increase in the expression of BMPER in the process of fat accumulation and adipocyte differentiation.
도 4는 BMPER siRNA를 이용하여, BMPER 발현을 억제하여 지방의 축적 및 지방세포 분화를 감소시키는 것을 나타낸 도이다.4 is a diagram showing the reduction of fat accumulation and adipocyte differentiation by inhibiting BMPER expression using BMPER siRNA.
도 5는 다양한 세포에서 CLUH 발현량을 관찰한 결과이다.5 shows the results of observing the expression level of CLUH in various cells.
도 6은 다양한 세포에서 BMPER 발현량을 관찰한 결과이다.6 shows the results of observing BMPER expression in various cells.
상기 목적을 달성하기 위하여, 본 발명의 일 양태는 CLUH (Clustered mitochondrial homolog) 및 BMPER (BMP binding endothelial regulator) 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 비만 치료 또는 예방용 약학 조성물을 제공한다. 상기 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 것일 수 있다. In order to achieve the above object, an aspect of the present invention is an agent that inhibits the expression or activity of at least one protein of CLUH (Clustered mitochondrial homolog) and BMPER (BMP binding endothelial regulator) protein, or the gene encoding the at least one protein It provides a pharmaceutical composition for treating or preventing obesity. The composition may include CLUH, BMPER, or an agent that inhibits the expression or activity of CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 용어 "CLUH (Clustered mitochondrial homolog)"란, 미토콘드리아 관련 유전자로서, 미토콘드리아의 생체 내 합성을 조절하는 것으로 알려져있다. 상기 CLUH을 코딩하는 유전자의 구체적인 염기서열 및 단백질 정보는 NCBI의 GeneBank 등 공지의 데이터베이스에서 얻을 수 있다(예를 들어, NM_001081158.2, NP_001074627.1.) 그러나, 상기 공지된 서열뿐만 아니라, 상기 CLUH와 동일하게 지방세포의 분화를 유도하고 지방축적을 유도하는 효과를 나타내는 한, 이의 상동 단백질 또는 변이 단백질 역시 본 발명에서 제공하는 CLUH의 범주에 포함될 수 있다. 구체적으로, 상기 CLUH을 코딩하는 유전자의 구체적인 염기서열은 서열번호 5일 수 있으나, 이에 제한되지 않는다. The term "CLUH (Clustered mitochondrial homolog)" of the present invention is a mitochondrial related gene and is known to regulate in vivo synthesis of mitochondria. Specific sequencing and protein information of the gene encoding the CLUH can be obtained from a known database such as GeneBank of NCBI (for example, NM_001081158.2, NP_001074627.1.) However, in addition to the known sequence, the CLUH As long as it exhibits the effect of inducing differentiation of fat cells and inducing fat accumulation, homologous proteins or variant proteins thereof may also be included in the scope of CLUH provided by the present invention. Specifically, the specific base sequence of the gene encoding the CLUH may be SEQ ID NO: 5, but is not limited thereto.
본 발명의 용어 "BMPER (BMP binding endothelial regulator)"란, 뼈 형성 단백질 (bone morphogenetic protein, BMP)과 결합하여 이의 기능을 억제하는 단백질을 말한다. 상기 단백질은 BMP2- 및 BMP4-의존적 조골세포 (osteoblast) 분화와 BMP-의존적인 연골원 (chondrogenic) 세포의 분화를 억제하는 것으로 알려져 있다. 상기 단백질을 코딩하는 유전자의 변이는 심각한 골격 질환과 관계된 것으로 알려져 있다. 상기 BMPER을 코딩하는 유전자의 구체적인 염기서열 및 단백질 정보는 NCBI의 GeneBank 등 공지의 데이터베이스에서 얻을 수 있다(예를 들어, NM_028472.2, NP_082748.1) 그러나, 상기 공지된 서열뿐만 아니라, 상기 BMPER과 동일하게 지방세포의 분화를 유도하고 지방축적을 유도하는 효과를 나타내는 한, 이의 상동 단백질 또는 변이 단백질 역시 본 발명에서 제공하는 BMPER의 범주에 포함될 수 있다. 구체적으로, 상기 BMPER을 코딩하는 유전자의 구체적인 염기서열은 서열번호 10일 수 있으나, 이에 제한되지 않는다. As used herein, the term "BMPER (BMP binding endothelial regulator)" refers to a protein that binds to bone morphogenetic protein (BMP) and inhibits its function. The protein is known to inhibit BMP2- and BMP4-dependent osteoblast differentiation and BMP-dependent chondrogenic cell differentiation. Mutations in the gene encoding the protein are known to be associated with severe skeletal disease. Specific base sequence and protein information of the gene encoding the BMPER can be obtained from a known database such as GeneBank of NCBI (for example, NM_028472.2, NP_082748.1). However, in addition to the known sequence, Equally, homologous proteins or variant proteins thereof may also be included in the scope of the BMPER provided by the present invention, as long as they exhibit the effect of inducing differentiation of fat cells and inducing fat accumulation. Specifically, the specific base sequence of the gene encoding the BMPER may be SEQ ID NO: 10, but is not limited thereto.
본 발명에서, CLUH 및 BMPER의 발현을 모두 억제하거나 또는 발현량을 함으로써, 또는 CLUH 및 BMPER 중 어느 하나의 발현을 억제하거나 발현량을 측정 함으로써, 지방세포로의 분화 억제, 비만의 진단, 예방, 또는 치료, 비만 치료제 또는 분화 조절제의 스크리닝 및 효능 검정을 할 수 있다. In the present invention, by inhibiting or expressing both the expression of CLUH and BMPER, or by inhibiting the expression or measuring the expression level of either CLUH and BMPER, inhibiting differentiation into adipocytes, diagnosing, preventing, or Screening and efficacy assays for treatment, anti-obesity agents or differentiation modulators can be performed.
본 발명에서 용어, "상동성(homology)"은 야생형(wild type) 단백질의 아미노산 서열 또는 이를 코딩하는 염기 서열과의 유사한 정도를 나타내기 위한 것으로서, 본 발명의 아미노산 서열 또는 염기 서열과 상기와 같은 퍼센트 이상의 동일한 서열을 가지는 서열을 포함한다. 이러한 상동성은 두 서열을 육안으로 비교하여 결정할 수도 있으나, 비교대상이 되는 서열을 나란히 배열하여 상동성 정도를 분석해 주는 생물정보 알고리즘(bioinformatic algorithm)을 사용하여 결정할 수 있다. 상기 두 개의 아미노산 서열 사이의 상동성은 백분율로 표시할 수 있다. 유용한 자동화된 알고리즘은 Wisconsin Genetics Software Package (Genetics Computer Group, Madison, W, USA)의 GAP, BESTFIT, FASTA와 TFASTA 컴퓨터 소프트웨어 모듈에서 이용가능하다. 상기 모듈에서 자동화된 배열 알고리즘은 Needleman & Wunsch와 Pearson & Lipman과 Smith & Waterman 서열 배열 알고리즘을 포함한다. 다른 유용한 배열에 대한 알고리즘과 상동성 결정은 FASTP, BLAST, BLAST2,PSIBLAST와 CLUSTAL W를 포함하는 소프트웨어에서 자동화되어 있다.As used herein, the term "homology" is intended to indicate a degree of similarity to the amino acid sequence of a wild type protein or a base sequence encoding the same, and the amino acid sequence or base sequence of the present invention and Includes sequences having more than one percent identical sequence. Such homology may be determined by visually comparing two sequences, but may be determined using a bioinformatic algorithm that analyzes the degree of homology by arranging the sequences to be compared side by side. Homology between the two amino acid sequences can be expressed as a percentage. Useful automated algorithms are available in the GAP, BESTFIT, FASTA and TFASTA computer software modules of the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, W, USA). Automated alignment algorithms in this module include Needleman & Wunsch and Pearson & Lipman and Smith & Waterman sequence alignment algorithms. Algorithms and homology determinations for other useful arrays are automated in software including FASTP, BLAST, BLAST2, PSIBLAST and CLUSTAL W.
본 발명의 용어 "발현 또는 활성을 억제할 수 있는 제제"란, 유전자에서 발현되어 생산되는 전사체 또는 단백질의 생성을 억제할 수 있는 물질을 의미한다. 상기 제제로는 유전자에 결합하여 전사수준에서 억제하는 전사인자; 전사되어 합성된 전사체에 결합하여 전사체를 분해하는 miRNA, siRNA, shRNA 등의 간섭 RNA; 상기 CLUH 또는 BMPER의 발현을 억제하거나 활성을 억제하는 화합물, 그 예로 저분자 화합물질; 발현된 단백질과 결합할 수 있는 항체, 앱타머, 안타고니스트 등이 될 수 있으나, 이에 제한되지 않는다.As used herein, the term "agent capable of inhibiting expression or activity" refers to a substance capable of inhibiting the production of a transcript or protein expressed and produced in a gene. The agent includes a transcription factor that binds to a gene and inhibits it at the transcription level; Interfering RNA such as miRNA, siRNA, shRNA, etc., which bind to the transcript that is transcribed and synthesized to degrade the transcript; Compounds which inhibit the expression or inhibit the activity of the CLUH or BMPER, such as low molecular weight compounds; It may be an antibody, aptamer, antagonist, etc. which can bind to the expressed protein, but is not limited thereto.
본 발명의 용어 "간섭 RNA(short interfering RNA)"란, 유전자의 활성을 억제하는 RNAi를 유발시킬 수 있는 이중가닥 RNA를 의미한다. 본 발명에 있어서 상기 간섭 RNA는 CLUH 또는 BMPER의 발현을 억제할 수 있는 miRNA, siRNA, shRNA 등이 될 수 있는데, 상기 간섭 RNA는 CLUH 또는 BMPER 유전자의 발현 또는 활성을 억제시키기만 하면 어떠한 형태의 것도 가능하다. 예를 들면, 화학합성 또는 생화학적 합성 또는 생체내 합성에 의해 수득되는 siRNA, 혹은 약 40개 염기 이상의 이중가닥 RNA가 체내에서 분해된 10개 염기대 이상의 이중가닥 RNA 등을 사용할 수 있다.  As used herein, the term "short interfering RNA" refers to double-stranded RNA capable of inducing RNAi that inhibits the activity of a gene. In the present invention, the interference RNA may be miRNA, siRNA, shRNA, etc., which can inhibit the expression of CLUH or BMPER, but the interference RNA may be in any form as long as it inhibits the expression or activity of the CLUH or BMPER gene. It is possible. For example, siRNA obtained by chemical synthesis or biochemical synthesis or in vivo synthesis, or 10 base band or more double stranded RNA in which about 40 bases or more of double stranded RNA is degraded in the body can be used.
구체적으로, CLUH의 발현을 억제하는 siRNA는 서열번호 3의 siRNA, 또는 서열번호 4의 siRNA 등이 될 수 있으나, 이에 제한되는 것은 아니다. Specifically, siRNA that inhibits the expression of CLUH may be siRNA of SEQ ID NO: 3, or siRNA of SEQ ID NO: 4, but is not limited thereto.
또한, BMPER의 발현을 억제하는 siRNA는 서열번호 8의 siRNA, 또는 서열번호 9의 siRNA 등이 될 수 있으나, 이에 제한되는 것은 아니다. In addition, siRNA that inhibits the expression of BMPER may be siRNA of SEQ ID NO: 8, or siRNA of SEQ ID NO: 9, but is not limited thereto.
상기 간섭 RNA는 상기 각 단백질을 코딩하는 유전자의 일부에 대하여 이에 제한되지 않으나 구체적으로 약 70% 이상, 75% 이상, 80% 이상, 85% 이상, 90% 이상, 95% 이상 또는 100%의 상동성을 가지는 서열로 구성될 수 있고, 이중가닥 부분을 포함하는 RNA 또는 그의 개변체를 사용할 수도 있다. The interfering RNA is not limited to some of the genes encoding the respective proteins, but specifically about 70%, 75%, 80%, 85%, 90%, 95% or 100% It may be composed of homologous sequences, and RNA or modified variants thereof including double stranded portions may be used.
본 발명의 용어 “저분자 화합물질”이란, 상기 CLUH 또는 BMPER의 발현을 억제하거나 활성을 억제할 수 있는 한, 제한되지 않고 본 발명에 포함될 수 있으며, 천연 유래의 물질 또는 합성된 물질일 수 있다. 구체적으로, 유기합성물질, 또는 천연물질 일 수 있다.As used herein, the term “low molecular weight compound” is not limited, and may be included in the present invention as long as it can suppress the expression or inhibit the activity of CLUH or BMPER, and may be a substance derived from nature or a synthesized substance. Specifically, it may be an organic synthetic material or a natural material.
본 발명의 용어 "항체"란, 단백질 또는 펩티드 분자의 항원성 부위에 특이적으로 결합할 수 있는 단백질성 분자를 의미하는데, 이러한 항체는, 각 유전자를 통상적인 방법에 따라 발현벡터에 클로닝하여 상기 마커 유전자에 의해 코딩되는 단백질을 얻고, 얻어진 단백질로부터 통상적인 방법에 의해 제조될 수 있다. 상기 항체의 형태는 특별히 제한되지 않으며 폴리클로날 항체, 모노클로날 항체 또는 항원 결합성을 갖는 것이면 그것의 일부도 본 발명의 항체에 포함되고 모든 면역 글로불린 항체가 포함될 수 있을 뿐만 아니라, 인간화 항체 등의 특수 항체를 포함할 수도 있다. 아울러, 상기 항체는 2개의 전체 길이의 경쇄 및 2개의 전체 길이의 중쇄를 가지는 완전한 형태뿐만 아니라 항체 분자의 기능적인 단편을 포함한다. 항체 분자의 기능적인 단편이란 적어도 항원 결합 기능을 보유하고 있는 단편을 의미하며 Fab, F(ab'), F(ab')2 및 Fv 등이 될 수 있다. 본 발명의 목적상, 상기 항체는 CLUH 또는 BMPER 단백질에 특이적으로 결합할 수 있는 항체가 될 수 있다.As used herein, the term "antibody" refers to a proteinaceous molecule capable of specifically binding to an antigenic site of a protein or peptide molecule. Such an antibody may be prepared by cloning each gene into an expression vector according to a conventional method. The protein encoded by the marker gene can be obtained and prepared by conventional methods from the obtained protein. The form of the antibody is not particularly limited and, if it is a polyclonal antibody, a monoclonal antibody or antigen-binding, a part thereof may be included in the antibody of the present invention and may include all immunoglobulin antibodies, as well as humanized antibodies. It may also contain a special antibody of. In addition, the antibodies include functional fragments of antibody molecules as well as complete forms having two full length light chains and two full length heavy chains. A functional fragment of an antibody molecule means a fragment having at least antigen binding function and may be Fab, F (ab '), F (ab') 2 and Fv. For the purposes of the present invention, the antibody may be an antibody that can specifically bind to CLUH or BMPER protein.
본 발명의 용어 "앱타머(aptamer)"란, 소정의 표적 분자에 대한 결합 활성을 갖는 핵산 분자를 의미한다. 상기 앱타머는 RNA, DNA, 수식(modified) 핵산 또는 이들의 혼합물일 수 있으며, 직쇄상 또는 환상의 형태일 수 있는데, 대체로, 상기 앱타머를 구성하는 뉴클레오티드의 서열이 짧을수록 화학합성 및 대량 생산이 보다 용이하고, 비용면에서의 장점이 우수하며, 화학수식이 용이하고, 생체 내 안정성이 우수하며, 독성이 낮다고 알려져 있다.As used herein, the term "aptamer" refers to a nucleic acid molecule having binding activity to a given target molecule. The aptamers may be RNA, DNA, modified nucleic acids, or mixtures thereof, and may be linear or cyclic. In general, the shorter the sequence of nucleotides constituting the aptamer, the more chemical synthesis and mass production. It is known to be easier, cost-effective, easy to modify chemical formula, excellent in vivo stability and low toxicity.
본 발명의 목적상 상기 앱타머는 CLUH 또는 BMPER 단백질에 결합함으로써, 상기 단백질의 활성을 억제할 수 있는 수단으로 해석될 수 있다. For the purposes of the present invention, the aptamer may be interpreted as a means capable of inhibiting the activity of the protein by binding to the CLUH or BMPER protein.
본 발명의 용어 "안타고니스트(antagonist)"란, 수용체의 생물학적 활성을 직접 또는 간접적으로 감소시킬 수 있는 분자를 의미하며, 수용체의 리간드와 함께 사용하는 경우에 상기 리간드의 작용을 감소시킬 수 있는 분자를 포함하나, 이에 제한되지 않는다. As used herein, the term "antagonist" refers to a molecule capable of directly or indirectly reducing a biological activity of a receptor, and when used with a ligand of a receptor, a molecule capable of reducing the action of the ligand is used. Including but not limited to.
본 발명의 목적상 상기 안타고니스트는 CLUH 또는 BMEPR 단백질의 활성을 억제하는 분자라면 제한 없이 포함하며, 구체적인 예로 상기 안타고니스트는 CLUH 또는 BMPER 단백질에 결합하여 활성을 억제하는 분자를 의미하나, 이에 제한되지 않는다. For the purposes of the present invention, the antagonist includes a molecule which inhibits the activity of CLUH or BMEPR protein without limitation, and in particular, the antagonist means a molecule that inhibits activity by binding to CLUH or BMPER protein, but is not limited thereto.
본 발명의 용어 "비만" 이란, 에너지 불균형에 의하여 과다한 체지방을 가진 상태(condition) 또는 질환(disease)을 의미한다. 본 발명에 따른 약학 조성물을 개체에 투여함으로써 체중을 감량하여 비만을 예방 또는 치료할 수 있다.As used herein, the term "obesity" means a condition or disease with excess body fat due to energy imbalance. By administering the pharmaceutical composition according to the present invention to a subject, weight can be reduced to prevent or treat obesity.
본 발명의 용어 "예방"이란, 본 발명에 따른 약학적 조성물의 투여로 비만의 발병을 억제 또는 지연시키는 모든 행위를 의미한다.The term "prevention" of the present invention means any action that inhibits or delays the development of obesity by administration of the pharmaceutical composition according to the present invention.
본 발명의 일 실시예에 의하면, 3T3-L1 세포주를 이용하여, 지방세포로의 분화 및 지방 축적과 CLUH 또는 BMPER의 관련성을 확인한 결과, 지방세포로의 분화 및 지방 축적 과정에서 CLUH 또는 BMPER의 발현이 증대되는 것을 확인하였다 (도 1 및 3). According to one embodiment of the present invention, using the 3T3-L1 cell line, as a result of confirming the relationship between the differentiation and fat accumulation of adipocytes and CLUH or BMPER, the expression of CLUH or BMPER is increased during the differentiation and adipocyte accumulation process to adipocytes It was confirmed that (Figs. 1 and 3).
본 발명의 다른 실시예에 의하면, siRNA를 이용하여 CLUH 또는 BMPER의 발현을 억제하였을 때 지방세포로의 분화가 억제되며, 지방 축적 역시 감소하는 것을 확인하였다(도 2 및 4).According to another embodiment of the present invention, when the expression of CLUH or BMPER is suppressed using siRNA, differentiation into adipocytes is inhibited and fat accumulation is also reduced (FIGS. 2 and 4).
본 발명의 또 다른 실시예에 의하면, 인간 간엽줄기세포(human mesenchymal stem cell), 및 생쥐의 지방 전구세포인 3T3L1, C3H10T1/2의 지방세포로의 분화 과정에서 CLUH 또는 BMPER 발현량을 측정한 결과, CLUH 또는 BMPER 발현량이 증대됨을 확인하였다 (도 5 및 6).According to another embodiment of the present invention, as a result of measuring the expression level of CLUH or BMPER in the differentiation process of human mesenchymal stem cells and the adipocytes of mouse fat progenitor cells 3T3L1, C3H10T1 / 2, It was confirmed that the expression level of CLUH or BMPER was increased (FIGS. 5 and 6).
따라서, 본 발명자들은 CLUH 또는 BMPER이 지방세포로의 분화 및 지방 축적에 관여되어, 이의 발현을 조절함으로써 비만을 예방 또는 치료 할 수 있으며, 더 나아가 이의 발현수준을 측정하여 비만을 진단하거나 비만 치료제를 스크리닝 할 수 있음을 알 수 있었다. Therefore, the present inventors can prevent or treat obesity by controlling the expression of CLUH or BMPER into adipocytes and accumulating fat, and furthermore, by measuring its expression level, diagnosing obesity or screening for obesity treatment I could see that.
본 발명의 약학적 조성물은, 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 추가로 포함하는 비만 치료 또는 예방용 약학 조성물의 형태로 제조될 수 있는데, 상기 담체는 비자연적 담체(non-naturally occuring carrier)를 포함할 수 있다. 구체적으로, 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에서, 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는 데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The pharmaceutical composition of the present invention may be prepared in the form of a pharmaceutical composition for treating or preventing obesity, further comprising a suitable carrier, excipient, or diluent commonly used in the manufacture of the pharmaceutical composition, wherein the carrier is an unnatural carrier. (non-naturally occuring carrier). Specifically, the pharmaceutical composition may be formulated in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods. Can be. In the present invention, carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid form forms at least one excipient such as starch, calcium carbonate, sucrose or lactose. (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used. Liquid preparations for oral use may include various excipients, such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to water and liquid paraffin, which are commonly used to include suspensions, solutions, emulsions, and syrups. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 약학 조성물에 포함된 상기 제제의 함량은 특별히 이에 제한되지 않으나, 최종 조성물 총중량을 기준으로 0.0001 내지 50 중량%, 보다 바람직하게는 0.01 내지 10 중량%의 함량으로 포함할 수 있다. The content of the formulation included in the pharmaceutical composition of the present invention is not particularly limited, but may be included in an amount of 0.0001 to 50% by weight, more preferably 0.01 to 10% by weight based on the total weight of the final composition.
상기 본 발명의 약학 조성물은 약학적으로 유효한 양으로 투여될 수 있는데, 본 발명의 용어 "약제학적으로 유효한 양"이란 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명의 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, the term "pharmaceutically effective amount" of the present invention is to treat or prevent the disease at a reasonable benefit / risk ratio applicable to medical treatment or prevention Sufficient amount means an effective dose level means the severity of the disease, the activity of the drug, the age, weight, health, sex, sensitivity of the patient to the drug, the time of administration of the composition of the invention used, the route of administration and the rate of excretion The duration of treatment, factors including drugs used in combination or coincidental with the composition of the invention used, and other factors well known in the medical art can be determined. The pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. In consideration of all the above factors, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects.
본 발명의 약학조성물의 투여량은 사용목적, 질환의 중독도, 환자의 연령, 체중, 성별, 기왕력, 또는 유효성분으로서 사용되는 물질의 종류 등을 고려하여 당업자가 결정할 수 있다. 예를 들어, 본 발명의 약학 조성물을 사람을 포함하는 포유동물에 하루 동안 10 내지 100 ㎎/㎏, 보다 바람직하게는 10 내지 30 ㎎/㎏으로 투여할 수 있고, 본 발명의 조성물의 투여빈도는 특별히 이에 제한되지 않으나, 1일 1회 내지 3회 투여하거나 또는 용량을 분할하여 수회 투여할 수 있다.The dosage of the pharmaceutical composition of the present invention can be determined by those skilled in the art in consideration of the purpose of use, the degree of addiction of the disease, the age, weight, sex, history, or type of substance used as an active ingredient. For example, the pharmaceutical composition of the present invention may be administered to a mammal, including humans, at 10 to 100 mg / kg, more preferably 10 to 30 mg / kg, per day, and the frequency of administration of the composition of the present invention may be The present invention is not limited thereto, but may be administered once to three times a day or several times in divided doses.
본 발명은 다른 양태로서, 비만 치료 또는 예방용 약학 조성물을 비만 또는 비만의 발병 위험이 있는 개체에 투여하는 단계를 포함하는, 비만의 예방 또는 치료 방법을 제공한다. 상기 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 것일 수 있다. In another aspect, the present invention provides a method for preventing or treating obesity, comprising administering a pharmaceutical composition for treating or preventing obesity to an individual at risk of developing obesity or obesity. The composition may include CLUH, BMPER, or an agent that inhibits the expression or activity of CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 용어 "예방"은 상술한 바와 같다.The term "prevention" of the present invention is as described above.
본 발명의 용어 "치료"란, 본 발명의 약학 조성물을 투여함으로써, 비만의 증세가 호전되거나 이롭게 변경시키는 모든 행위를 의미한다. The term "treatment" of the present invention means any action that improves or advantageously changes the condition of obesity by administering the pharmaceutical composition of the present invention.
본 발명의 비만 치료 또는 예방용 약학 조성물의 투여를 통한 비만의 예방 또는 치료 방법으로, 비만인 개체에서 비만의 증세가 호전되거나 이롭게 될 수 있고, 또는 비만의 발병이 의심되거나 비만 발병의 위험이 있는 개체의 비만이 발병되지 않도록 저해할 수 있다.A method for preventing or treating obesity through the administration of a pharmaceutical composition for treating or preventing obesity, which may improve or benefit the symptoms of obesity in an obese individual, or suspect an onset of obesity or a risk of developing obesity Obesity can be prevented from developing.
본 발명은 또 다른 양태로서, CLUH (Clustered mitochondrial homolog) 및 BMPER (BMP binding endothelial regulator) 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 수준을 측정하는 제제를 포함하는 비만 진단용 조성물을 제공한다.In still another aspect, the present invention provides a composition for diagnosing obesity, comprising an agent for measuring the expression level of one or more proteins of a clustered mitochondrial homolog (CLUH) and a BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins. To provide.
상기 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 수준을 측정하는 제제를 포함하는 것일 수 있다. The composition may include a CLUH, BMPER, or an agent for measuring the expression level of the CLUH and BMPER protein or the gene encoding the protein.
본 발명의 용어, “CLUH (Clustered mitochondrial homolog)”, 및 "BMPER (BMP binding endothelial regulatr)"는 상술한 바와 같다.The terms "Clustered mitochondrial homolog" (CLUH), and "BMP binding endothelial regulatr" (BMPER) are as described above.
본 발명의 용어, “단백질의 수준 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정할 수 있는 제제”는, 구체적으로, 상기 CLUH 또는 BMPER 유전자의 mRNA에 특이적으로 결합하는 안티센스 올리고뉴클레오티드, 프라이머 쌍, 프로브 또는 상기 CLUH 또는 BMPER 단백질에 특이적으로 결합하는 항체, 앱타머, 안타고니스트 및 이들의 조합으로 이루어진 군으로부터 선택된 것 일 수 있으나, 이에 제한되는 것은 아니다. As used herein, the term “agent capable of measuring the level of a protein or expression level of a gene encoding the protein” specifically refers to an antisense oligonucleotide, primer pair that specifically binds to mRNA of the CLUH or BMPER gene. , But may be selected from the group consisting of probes or antibodies, aptamers, antagonists, and combinations thereof that specifically bind to the CLUH or BMPER protein, but is not limited thereto.
상기 항체, 앱타머, 및 안타고니스트는 상술한 바와 동일하다.The antibodies, aptamers, and antagonists are the same as described above.
본 발명의 용어 "프라이머"란, 짧은 자유 3말단 수산화기(free 3' hydroxyl group)를 가지는 핵산 서열로 상보적인 템플레이트(template)와 염기쌍(base pair)을 형성할 수 있고 템플레이트 가닥 복사를 위한 시작 지점으로 기능을 하는 짧은 핵산 서열을 의미한다. 프라이머는 적절한 완충용액 및 온도에서 중합반응(즉, DNA 폴리머레이즈 또는 역전사효소)을 위한 시약 및 상이한 4가지 뉴클레오사이드 트리포스페이트의 존재하에서 DNA 합성을 개시할 수 있다. PCR 조건, 센스 및 안티센스 프라이머의 길이는 당업계에 공지된 것을 기초로 변형할 수 있다. 또한, 상기 프라이머는 변형시킬 수 있으며, 예를 들어 메틸화, 캡화, 뉴클레오타이드의 치환 또는 뉴클레오타이드 간의 변형, 예를 들면, 하전되지 않은 연결체(예: 메틸 포스포네이트, 포스포트리에스테르, 포스포로아미데이트, 카바메이트 등) 또는 하전된 연결체(예: 포스포로티오에이트, 포스포로디티오에이트 등)로의 변형이 있을 수 있다. 아울러, 상기 프라이머 쌍을 사용하여 증폭시킨 PCR 산물을 보다 효과적으로 인식하기 위하여, 상기 프라이머의 5' 또는 3' 말단에 형광물질 등으로 표지할 수 있다. 이때, 사용되는 형광물질은 특별히 이에 제한되지 않으나, FAM(6-carboxyfluorescein), HEX(2',4',5',7',-tetrachloro-6-carboxy-4,7-dichlorofluorescein), NED™ 등을 사용할 수 있다. 구체적으로, 본 발명의 프라이머 쌍은 서열번호 1 및 2; 또는 서열번호 6 및 7의 서열을 가지는 프라이머일 수 있으나, 이에 제한되는 것은 아니다.As used herein, the term "primer" refers to a nucleic acid sequence having a short free 3 'hydroxyl group, which can form complementary templates and base pairs and is the starting point for template strand copying. It refers to a short nucleic acid sequence that functions as. Primers can initiate DNA synthesis in the presence of four different nucleoside triphosphates and reagents for polymerization (ie, DNA polymerase or reverse transcriptase) at appropriate buffers and temperatures. PCR conditions, sense and antisense primer lengths can be modified based on what is known in the art. In addition, the primers can be modified, for example methylation, encapsulation, substitution of nucleotides or modifications between nucleotides, for example uncharged linkages such as methyl phosphonate, phosphoester, phosphoroamidate , Carbamate, etc.) or charged linkers (eg, phosphorothioate, phosphorodithioate, etc.). In addition, in order to recognize the PCR product amplified using the primer pair more effectively, the 5 'or 3' end of the primer may be labeled with a fluorescent material or the like. At this time, the fluorescent material used is not particularly limited, but FAM (6-carboxyfluorescein), HEX (2 ', 4', 5 ', 7',-tetrachloro-6-carboxy-4,7-dichlorofluorescein), NED ™ Etc. can be used. Specifically, primer pairs of the present invention include SEQ ID NOs: 1 and 2; Or it may be a primer having a sequence of SEQ ID NO: 6 and 7, but is not limited thereto.
본 발명의 용어 "프로브"란, 유전자 또는 mRNA와 특이적 결합을 이룰 수 있는 짧게는 수 염기 내지 길게는 수백 염기에 해당하는 RNA 또는 DNA 등의 핵산 단편을 의미하는데, 올리고뉴클레오티드(oligonucleotide) 프로브, 단쇄 DNA(single stranded DNA) 프로브, 이중쇄 DNA(double stranded DNA) 프로브, RNA 프로브 등의 형태로 제작될 수 있고, 보다 용이하게 검출하기 위하여 라벨링될 수 있다.As used herein, the term “probe” refers to a nucleic acid fragment such as RNA or DNA, which may correspond to a short base to several hundred bases, which may achieve specific binding with a gene or mRNA, and includes an oligonucleotide probe, It may be prepared in the form of single stranded DNA probe, double stranded DNA probe, RNA probe, or the like, and may be labeled for easier detection.
본 발명의 용어, "진단"이란, 병리 상태의 존재 또는 특징을 확인하는 것으로서, 본 발명의 목적상, 비만 여부를 확인하는 것일 수 있다.The term "diagnosis" of the present invention refers to confirming the presence or characteristics of a pathological state, and for the purposes of the present invention, may be to confirm whether obesity exists.
본 발명의 비만 진단용 조성물을 이용하여, 정상인과 비만이 의심되는 개체로부터 분리된 시료의 CLUH 또는 BMPER 단백질 또는 단백질을 코딩하는 유전자의 발현 수준을 측정하여 비만이 의심되는 개체의 CLUH 또는 BMPER 단백질 또는 이를 코딩하는 유전자의 발현 수준이 정상인보다 증가된 경우, 비만으로 판정할 수 있다. 이 때, 정상인은 비만이 아닌 개체를 의미한다.Using the composition for diagnosing obesity, the CLUH or BMPER protein or a gene encoding the protein of a sample isolated from a normal person and a subject suspected of obesity is measured to determine the CLUH or BMPER protein of the subject suspected of obesity or the same. Obesity can be determined when the expression level of the encoding gene is increased than normal. In this case, the normal person means an individual who is not obese.
본 발명은 또 다른 양태로서, 상기 비만 진단용 조성물을 포함하는, 비만 진단용 키트를 제공한다. As another aspect, the present invention provides a kit for diagnosing obesity, comprising the composition for diagnosing obesity.
상기 비만 진단용 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 것일 수 있다. The diagnostic composition for obesity may include a CLUH, BMPER, or an agent for measuring the expression level of the CLUH and BMPER protein or the gene encoding the protein.
본 발명의 "키트"는 최적의 반응 수행 조건을 기재한 사용설명서를 추가로 포함할 수 있다. 사용설명서는 팜플렛 또는 전단지 형태의 안내 책자, 키트에 부착된 라벨, 및 키트를 포함하는 패키지의 표면상에 설명을 포함한다. 또한, 안내서는 인터넷과 같이 전기 매체를 통해 공개되거나 제공되는 정보를 포함할 수 있다.The "kit" of the present invention may further include instructions for describing optimal reaction performance conditions. Instructions include brochures in the form of pamphlets or leaflets, labels affixed to the kit, and instructions on the surface of the package containing the kit. In addition, the guide may include information disclosed or provided through an electronic medium such as the Internet.
상기 키트는 RT-PCR 키트 또는 DNA 분석용 (예, DNA 칩) 키트, 또는 단백질 칩 키트일 수 있다.The kit may be an RT-PCR kit or a DNA analysis (eg, DNA chip) kit, or a protein chip kit.
구체적인 일례로서, 본 발명의 키트는 RT-PCR을 수행하기 위해 필요한 필수 요소를 포함하는 키트일 수 있다. RT-PCR 키트는, CLUH 또는 BMPER에 대한 특이적인 각각의 프라이머 쌍 외에도 RT-PCR 키트는 테스트 튜브 또는 다른 적절한 컨테이너, 반응 완충액(pH 및 마그네슘 농도는 다양), 데옥시뉴클레오타이드(dNTPs), Taq-폴리머라아제 및 역전사효소와 같은 효소, DNase, RNAse 억제제, DEPC-수(DEPC-water), 멸균수 등을 포함할 수 있다. 또한 정량 대조군으로 사용되는 유전자에 특이적인 프라이머 쌍을 포함할 수 있다. As a specific example, the kit of the present invention may be a kit including essential elements necessary for performing RT-PCR. RT-PCR kits, in addition to each primer pair specific for CLUH or BMPER, RT-PCR kits can be used in test tubes or other appropriate containers, reaction buffers (variable in pH and magnesium concentrations), deoxynucleotides (dNTPs), Taq- Enzymes such as polymerase and reverse transcriptase, DNase, RNAse inhibitors, DEPC-water, sterile water, and the like. It may also include primer pairs specific for the gene used as a quantitative control.
DNA 칩 키트는, 일반적으로 편평한 고체 지지판, 전형적으로는 현미경용 슬라이드보다 크지 않은 유리 표면에 핵산 종을 격자형 배열(gridded array)로 부착한 것으로, 칩 표면에 핵산이 일정하게 배열되어, DNA 칩 상의 핵산과 칩 표면에 처리된 용액 내에 포함된 상보적인 핵산 간에 다중 혼성화(hybridization) 반응이 일어나 대량 병렬 분석이 가능하도록 하는 도구이다.DNA chip kits are those in which a nucleic acid species is attached in a gridded array to a glass surface that is generally no larger than a flat solid support plate, typically a microscope slide. The hybridization between the nucleic acid of the phase and the complementary nucleic acid contained in the solution treated on the surface of the chip (hybridization) is a tool that allows massively parallel analysis.
상기 단백질 칩 키트는 마커에 대한 하나 이상의 항체가 기판 위의 정해진 위치에 배열되어 고밀도로 고정화되어 있는 키트일 수 있다. 단백질 칩을 이용하는 방법은 시료에서 단백질을 분리하고, 분리한 단백질을 단백질 칩과 혼성화시켜서 항원-항체 복합체를 형성하고, 이를 판독하여 단백질의 존재 또는 발현수준을 확인할 수 있다.The protein chip kit may be a kit in which one or more antibodies against a marker are arranged at a predetermined position on a substrate and immobilized at a high density. In the method using a protein chip, the protein is separated from the sample, and the separated protein is hybridized with the protein chip to form an antigen-antibody complex, which can be read to confirm the presence or expression level of the protein.
본 발명의 비만 진단용 키트를 이용하여, 비만이 의심되는 개체의 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 수준을 측정함으로써, 비만 여부를 판단할 수 있다.Obesity can be determined using the obesity diagnostic kit of the present invention by measuring the expression level of CLUH or BMPER protein or a gene encoding the protein of an obese subject in question.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 지방 세포 분화 억제용 조성물을 제공한다.In still another aspect, the present invention provides a composition for inhibiting adipocyte differentiation, which comprises an agent for inhibiting the expression or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 것일 수 있다. The composition may include CLUH, BMPER, or an agent that inhibits the expression or activity of CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 용어, “CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제”는 상술한 바와 같다.The term of the present invention, “an agent that inhibits the expression or activity of a CLUH or BMPER protein or a gene encoding said protein” is as described above.
본 발명의 지방 세포 분화 억제용 조성물은 CLUH 또는 BMPER의 발현 또는 활성을 억제시킴으로써, 지방 세포로의 분화를 억제할 수 있다. The composition for inhibiting adipocyte differentiation of the present invention can suppress differentiation into adipocytes by inhibiting the expression or activity of CLUH or BMPER.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 단계를 포함하는 비만의 진단 방법을 제공한다.In still another aspect, the present invention provides a method for diagnosing obesity, comprising measuring the expression level of one or more proteins of the CLUH and BMPER proteins, or a gene encoding the one or more proteins.
상기 비만의 진단 방법은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질의 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The diagnostic method of obesity may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
본 발명의 "비만의 진단 방법"은, 정상인과 비만이 의심되는 개체로부터 분리된 시료의 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 각각 측정하여 비만이 의심되는 개체의 CLUH 또는 BMPER 단백질 또는 이를 코딩하는 유전자의 발현수준이 정상인보다 증가된 경우, 비만으로 판정할 수 있다. 이 때, 정상인은 비만이 아닌 개체를 의미한다. The "diagnosis method of obesity" of the present invention, CLUH or BMPER of the subjects suspected of obesity by measuring the expression level of CLUH or BMPER protein or the gene encoding the protein, respectively, from samples isolated from normal and suspected obesity Obesity can be determined when the expression level of the protein or gene encoding it is increased than normal. In this case, the normal person means an individual who is not obese.
CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준의 측정은 상기 CLUH 또는 BMPER 유전자의 mRNA에 특이적으로 결합하는 안티센스 올리고뉴클레오티드, 프라이머 쌍, 프로브 또는 상기 CLUH 또는 BMPER 단백질에 특이적으로 결합하는 항체, 앱타머, 안타고니스트를 이용하여 측정할 수 있으나, 이에 제한되지 않는다. Determination of the expression level of a CLUH or BMPER protein or a gene encoding the protein can be performed by antisense oligonucleotides, primer pairs, probes that specifically bind to the mRNA of the CLUH or BMPER gene, or specifically binding to the CLUH or BMPER protein. It may be measured using an antibody, aptamer, antagonist, but is not limited thereto.
본 발명의 용어 "개체"란, 상기 비만이 발병될 가능성이 있거나, 또는 발병된 인간을 포함한 모든 동물을 의미한다. The term "individual" of the present invention means all animals, including humans, who are likely to develop or develop such obesity.
본 발명의 용어 "분리된 시료"란, 상기 개체로부터 분리되고, 상기 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 mRNA를 포함하여, 본 발명에서 상기 단백질 또는 유전자의 발현수준을 측정할 수 있는 시료를 의미하는데, 상기 시료는 특별히 이에 제한되지 않으나, 일 예로서, 분리된 조직 또는 분리된 세포가 될 수 있다.The term "isolated sample" of the present invention, which is isolated from the individual, including the mRNA of the CLUH or BMPER protein or the gene encoding the protein, in the present invention can measure the expression level of the protein or gene Meaning a sample, the sample is not particularly limited, but may be, for example, isolated tissue or separated cells.
본 발명은 또 다른 양태로서, (a) 비만 치료제 후보 물질을 CLUH 또는 BMPER 유전자가 발현되는 세포에 처리하는 단계; (b) 상기 (a) 단계에서 비만 치료제 후보 물질을 처리한 세포에서 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계; 및 (c) 상기 (b) 단계에서 측정한 발현량 또는 활성이 비만 치료제 후보 물질을 처리하지 않은 대조군 세포보다 감소하는 경우, 해당 비만 치료제 후보 물질을 비만 치료제로 판단하는 단계를 포함하는 비만 치료제의 스크리닝 방법을 제공한다.According to another aspect of the present invention, there is provided a method for treating a CLUH or BMPER gene, which comprises: (a) treating a candidate agent for treating obesity; (b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein, in cells treated with the anti-obesity agent candidate in step (a); And (c) when the expression amount or activity measured in step (b) is lower than that of the control cells that did not treat the obesity candidate drug substance, judging the candidate agent for obesity treatment as an obesity agent. It provides a screening method.
상기 비만 치료제의 스크리닝 방법은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질의 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The screening method of the anti-obesity agent may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
본 발명의 용어, “비만 치료제”는 비만인 개체에서 지방 세포 분화로의 억제를 유도하여, 체지방 감소, 지방 축적 저해, 체중 감소 등의 효과를 가지는 물질을 의미한다. 핵산, 단백질, 기타 추출물 또는 천연물, 또는 화합물 등이 될 수 있고, 구체적으로, 저분자 화합물, 유기합성물질, 천연물질, microRNA, siRNA, shRNA, 항체, 앱타머 등이 될 수 있으나, 이에 제한되지 않는다. As used herein, the term “therapeutic agent for obesity” refers to a substance that induces inhibition of adipocyte differentiation in an obese individual and has effects such as body fat reduction, fat accumulation inhibition, weight loss, and the like. Nucleic acids, proteins, other extracts or natural products, or compounds, and the like, and specifically, may be, but not limited to, low molecular weight compounds, organic synthetic materials, natural materials, microRNA, siRNA, shRNA, antibodies, aptamers, etc. .
본 발명의 용어, "비만 치료제 후보 물질"은 상기와 같은 비만 치료제가 될 수 있는 가능성이 있는 물질의 의미하는 것으로, 통상적인 선정방식에 따라 비만 치료의 가능성을 지닌 것으로 추정되거나 또는 무작위적으로 선정된 개별적인 핵산, 단백질, 기타 추출물 또는 천연물, 또는 화합물 등이 될 수 있고, 구체적으로, 저분자 화합물, 유기합성물질, 천연물질, microRNA, siRNA, shRNA, 항체, 앱타머 등이 될 수 있으나, 이에 제한되지 않는다. As used herein, the term “substance candidate for obesity” refers to a substance capable of becoming an anti-obesity agent as described above, and is estimated to have a possibility of treating obesity or randomly selected according to a conventional selection method. Individual nucleic acids, proteins, other extracts or natural products, or compounds, and the like, and specifically, may be low molecular weight compounds, organic compounds, natural materials, microRNAs, siRNAs, shRNAs, antibodies, aptamers, and the like. It doesn't work.
본 발명에서 단백질 또는 상기 단백질을 코딩하는 유전자의 발현량 또는 활성의 측정은 CLUH 또는 BMPER 단백질 또는 상기 유전자의 mRNA의 발현수준을 측정하는 것일 수 있다. In the present invention, the measurement of the expression level or activity of the protein or the gene encoding the protein may be to measure the expression level of the CLUH or BMPER protein or the mRNA of the gene.
구체적으로, 상기 CLUH 또는 BMPER 유전자의 mRNA 발현수준을 측정하는 것은 상기 유전자의 mRNA에 특이적으로 결합하는 안티센스 올리고뉴클레오티드, 프라이머 쌍, 프로브 또는 이들의 조합을 이용할 수 있고, 이는 역전사효소 중합효소반응, 경쟁적 역전사효소 중합효소반응, 실시간 역전사효소 중합효소반응, RNase 보호 분석법, 노던 블랏팅 및 DNA 마이크로어레이 칩으로 구성된 군으로부터 선택되는 분석법을 이용하여 수행될 수 있으나, 상기에 제한되지 않는다.Specifically, measuring the mRNA expression level of the CLUH or BMPER gene may use antisense oligonucleotides, primer pairs, probes or a combination thereof that specifically binds to the mRNA of the gene, which may include reverse transcriptase polymerase reaction, Competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting and DNA microarray chip can be performed using an assay selected from the group consisting of, but not limited to.
또한, 상기 CLUH 또는 BMPER 단백질의 발현수준을 측정하는 것은 상기 단백질에 특이적으로 결합하는 항체, 앱타머, 안타고니스트 또는 이들의 조합을 이용할 수 있고, 이는 웨스턴 블랏팅, ELISA, 방사선면역분석법, 방사면역확산법, 오우크레로니(Ouchterlony) 면역확산법, 로케트 면역전기영동, 면역조직화학염색, 면역침전분석, 보체고정분석, FACS 및 단백질 칩으로 구성된 군으로부터 선택되는 분석법을 이용하여 수행될 수 있으나, 상기에 제한되지 않는다.In addition, measuring the expression level of the CLUH or BMPER protein may use an antibody, aptamer, antagonist or a combination thereof that specifically binds to the protein, which may be Western blotting, ELISA, radioimmunoassay, radioimmunoassay. Diffusion method, Ouchterlony immunodiffusion method, rocket immunoelectrophoresis, immunohistochemical staining, immunoprecipitation analysis, complement fixation analysis, assays selected from the group consisting of FACS and protein chips, but can be performed It is not limited.
본 발명의 용어 "대조군"이란 비만 치료제 후보 물질을 처리하지 않은 CLUH 또는 BMPER을 발현하는 세포 또는 조직으로 상기 후보 물질을 처리한 군과 병렬 관계에 속하는 세포 또는 조직을 의미한다.As used herein, the term "control" refers to a cell or tissue expressing CLUH or BMPER that has not been treated with an anti-obesity candidate, and that is in a parallel relationship with the group treated with the candidate.
본 발명의 용어 “비만 치료제의 스크리닝 방법”은, 지방세포로 분화하는 과정에 CLUH 및 BMPER의 발현이 관련됨을 확인함으로써, 상기 CLUH 및 BMPER의 활성 및 발현을 치료제 후보 물질을 처리하지 않은 대조군 세포와 비교하는 방식으로 고안되었다. 비만을 예방 또는 치료할 수 있는 후보 물질의 부재 하에 세포에서의 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준을 측정하고, 또한, 상기 후보 물질의 존재 하에서 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준을 측정하여 양자를 비교한 후, 상기 후보 물질이 존재할 때의 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준이 상기 후보 물질의 부재 하에서의 수준보다 감소시키는 물질을 비만의 예방 또는 치료용 제제로 예측할 수 있다.The term "screening method of the obesity treatment agent" of the present invention, by identifying the expression of CLUH and BMPER involved in the process of differentiation into adipocytes, the activity and expression of the CLUH and BMPER and the control cells not treated with the candidate drug substance It is designed in a way of comparison. Measuring the expression level of the gene of the present invention or the level of the protein encoded by the gene in a cell in the absence of a candidate agent capable of preventing or treating obesity, and also in the presence of the candidate agent After comparing the two by measuring the expression level or the level of the protein encoded by the gene, the expression level of the gene of the present invention when the candidate substance is present or the level of the protein encoded by the gene is absent of the candidate substance. Substances that decrease below levels can be predicted as agents for the prevention or treatment of obesity.
이러한 스크리닝 방법에 의하여 얻어진 물질은 이후의 비만 예방 또는 치료제 개발 과정에서 선도물질(leading compound)로서 작용하게 되며, 선도 물질이 CLUH 또는 BMPER 또는 이를 암호화하는 유전자에 대한 저해 효과를 나타낼 수 있도록 그 구조를 변형시키고 최적화함으로써, 새로운 비만 예방 또는 치료제를 개발할 수 있으며, 이러한 물질은 CLUH 또는 BMPER 또는 이를 암호화하는 유전자에 대해 부분적 또는 완전한 활성 억제 효과를 나타내게 되므로 비만 관련 질환들을 예방 또는 치료할 수 있다.Substances obtained by this screening method will act as a leading compound in the future development of a prophylactic or therapeutic agent for obesity, and its structure may be modified so that the leading substance can exhibit an inhibitory effect on CLUH or BMPER or a gene encoding the same. By modifying and optimizing, new obesity prophylaxis or treatments can be developed, and these substances can have a partial or complete inhibitory effect on CLUH or BMPER or genes encoding them, thereby preventing or treating obesity-related diseases.
본 발명은 또 다른 양태로서, CLUH (Clustered mitochondrial homolog) 및 BMPER (BMP binding endothelial regulator) 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 비만 치료제의 스크리닝용 키트를 제공한다.In another aspect, the present invention provides a therapeutic agent for obesity comprising an agent for measuring the expression level of one or more proteins of the clustered mitochondrial homolog (CLUH) and the BMP binding endothelial regulator (BMPER), or a gene encoding the one or more proteins. Provided are kits for screening.
상기 비만 치료제의 스크리닝용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The kit for screening an obesity agent may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the protein.
본 발명의 비만 치료제의 스크리닝용 키트를 이용하여, 비만 치료제 후보 물질로부터 비만 치료제를 선정할 수 있다.Using the kit for screening an obesity therapeutic agent of the present invention, an obesity therapeutic agent can be selected from an obesity therapeutic candidate.
본 발명에서 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제, 및 키트는 상술한 바와 같다.In the present invention, the agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein, and the kit are as described above.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 비만 치료제의 효능 검정용 키트를 제공한다. In still another aspect, the present invention provides a kit for assaying efficacy of an obesity therapeutic agent comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 비만 치료제의 효능 검정용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The kit for assaying efficacy of the anti-obesity agent may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the protein.
본 발명에서 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제 및 키트는 상술한 바와 같다. Agents and kits for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein in the present invention are as described above.
본 발명의 "비만 치료제의 효능 검정용 키트"는 상기 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하고, 비만 치료제가 처리된 CLUH 또는 BMPER을 발현하는 세포에서 CLUH 또는 BMPER 단백질 또는 상기 유전자의 발현수준을 측정 가능한 키트일 수 있다. 상기 측정된 CLUH 또는 BMPER의 발현수준이 낮을수록 효과적인 비만 치료제인 것으로 검정할 수 있다. "Efficacy assay kit for the treatment of obesity agent" of the present invention includes an agent for measuring the expression level of the protein or the gene encoding the protein, CLUH or BMPER protein in cells expressing CLUH or BMPER treated with the anti-obesity agent Or it may be a kit capable of measuring the expression level of the gene. The lower the expression level of CLUH or BMPER measured above can be assayed as an effective obesity treatment.
본 발명의 "비만 치료제의 효능 검정용 키트"는 상기 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하고, 비만 치료제가 처리된 CLUH 또는 BMPER를 발현하는 세포에서 CLUH 또는 BMPER 단백질 또는 상기 유전자의 발현수준을 측정 가능한 키트일 수 있다. 상기 CLUH 또는 BMPER의 발현수준이 낮을수록 효과적인 비만 치료제인 것으로 검정할 수 있다. "Efficacy Assay Kit for Obesity Therapeutics" of the present invention includes an agent for measuring the expression level of the protein or the gene encoding the protein, and the CLUH or BMPER protein in cells expressing CLUH or BMPER treated with the anti-obesity agent Or it may be a kit capable of measuring the expression level of the gene. The lower the expression level of the CLUH or BMPER can be assayed as an effective obesity treatment.
본 발명은 또 다른 양태로서, (a) 지방세포 분화 촉진제 후보 물질을 CLUH 또는 BMPER 유전자가 발현되는 세포에 처리하는 단계; (b) 상기 (a) 단계에서 지방세포 분화 촉진제 후보 물질을 처리한 세포에서 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계; 및 (c) 상기 (b) 단계에서 측정한 발현량 또는 활성이 지방세포 분화 촉진제 후보 물질을 처리하지 않은 대조군 세포보다 감소하는 경우, 해당 지방세포 분화 촉진제 후보 물질을 지방세포 분화 촉진제로 판단하는 단계를 포함하는 지방세포 분화 촉진제의 스크리닝 방법을 제공한다.In still another aspect, the present invention provides a method for treating a cell comprising: (a) treating a candidate adipocyte differentiation candidate with a cell expressing a CLUH or BMPER gene; (b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein in cells treated with the adipocyte differentiation promoter candidate in step (a); And (c) determining the adipocyte differentiation candidate as an adipocyte differentiation promoter when the amount of expression or activity measured in step (b) is lower than that of the control cells not treated with the adipocyte differentiation candidate. It provides a method for screening adipocyte differentiation promoter comprising a.
상기 지방세포 분화 촉진제의 스크리닝 방법은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The screening method of the adipocyte differentiation promoter may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 용어, "지방세포 분화 조절제"는 지방세포로의 분화를 촉진하거나 억제할 수 있는 모든 물질 (핵산, 단백질, 기타 추출물 또는 천연물, 또는 화합물 등)을 의미하며, 구체적으로 상기 분화 조절제는 MLPH의 과발현을 유도하거나, 발현을 저해함으로써 지방세포로의 분화를 촉진하거나 억제할 수 있으며, 또는, 지방세포로의 분화 촉진 또는 억제 과정에서 MLPH의 발현량에 유의미한 변화를 일으킬 수 있는 물질이라면 본 발명에 포함된다. "지방세포 분화 촉진제" 및 "지방세포 분화 억제제"가 "지방세포 분화 조절제"에 포함된다.As used herein, the term "fat cell differentiation regulator" refers to any substance capable of promoting or inhibiting differentiation into adipocytes (nucleic acid, protein, other extract or natural product, or compound, etc.), and specifically, the differentiation regulator is MLPH. Induced over-expression or inhibiting expression can promote or inhibit differentiation into adipocytes, or any substance that can cause a significant change in the amount of MLPH expression in the process of promoting or inhibiting differentiation into adipocytes. do. "Fat cell differentiation promoter" and "fat cell differentiation inhibitor" are included in "fat cell differentiation regulator".
본 발명의 용어, "지방세포 분화 촉진제 후보 물질"은 통상적인 선정방식에 따라 지방 세포 분화를 촉진할 수 있는 가능성을 지닌 것으로 추정되거나 또는 무작위적으로 선정된 개별적인 핵산, 단백질, 기타 추출물 또는 천연물, 또는 화합물 등이 될 수 있고, 구체적으로, 저분자 화합물, 유기합성물질, 천연물질, microRNA, siRNA, shRNA, 항체, 앱타머 등이 될 수 있으나, 이에 제한되지 않는다.As used herein, the term "dipose cell differentiation promoter candidate" is a single nucleic acid, protein, other extract or natural product presumed to have the potential to promote adipocyte differentiation according to a conventional selection method or randomly selected; Or a compound, and the like, and specifically, may be a low molecular compound, an organic synthetic material, a natural material, a microRNA, siRNA, shRNA, an antibody, aptamer, and the like, but is not limited thereto.
본 발명의 용어 “단백질 또는 상기 단백질을 코딩하는 유전자의 발현량 또는 활성의 측정”, 및 “대조군”은 상술한 바와 같다. The terms "measurement of the amount or activity of expression of a protein or gene encoding said protein", and "control" are as described above.
본 발명의 용어 “지방세포 분화 촉진제의 스크리닝 방법”은, 지방세포로 분화하는 과정에 CLUH 또는 BMPER의 발현이 관련됨을 확인함으로써, CLUH 또는 BMPER의 활성 및 발현을 지방세포 분화 촉진제 후보 물질을 처리하지 않은 대조군 세포와 비교하는 방식으로 고안되었다. 지방세포의 분화를 촉진할 수 있는 후보 물질의 부재 하에 세포에서의 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준을 측정하고, 또한, 상기 후보 물질의 존재 하에서 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준을 측정하여 양자를 비교한 후, 상기 후보 물질이 존재할 때의 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준이 상기 후보 물질의 부재 하에서의 수준보다 증가시키는 물질을 지방세포 분화 촉진제로 예측할 수 있다.The term "screening method of adipocyte differentiation promoter" of the present invention confirms that expression of CLUH or BMPER is involved in the process of differentiating into adipocytes, thereby preventing the activity and expression of CLUH or BMPER to treat adipocyte differentiation candidate candidates. It was designed in a way that compares with control cells. Measuring the expression level of the gene of the present invention or the level of the protein encoded by the gene in the cell in the absence of a candidate agent capable of promoting the differentiation of adipocytes, and also in the presence of the candidate agent After comparing the two by measuring the expression level of the gene or the level of the protein encoded by the gene, the expression level of the gene of the present invention when the candidate substance is present or the level of the protein encoded by the gene is determined as the candidate substance. Substances that increase above the level in the absence of can be predicted as adipocyte differentiation promoters.
본 발명은 또 다른 양태로서, (a) 지방세포 분화 억제제 후보 물질을 CLUH 또는 BMPER 유전자가 발현되는 세포에 처리하는 단계; (b) 상기 (a) 단계에서 지방세포 분화 억제제 후보 물질을 처리한 세포에서 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계; 및 (c) 상기 (b) 단계에서 측정한 발현량 또는 활성이 지방세포 분화 억제제 후보 물질을 처리하지 않은 대조군 세포보다 감소하는 경우, 해당 지방세포 분화 억제제 후보 물질을 지방세포 분화 억제제로 판단하는 단계를 포함하는 지방세포 분화 억제제의 스크리닝 방법을 제공한다.In still another aspect, the present invention provides a method for treating a cell comprising: (a) treating an adipocyte differentiation inhibitor candidate to a cell expressing a CLUH or BMPER gene; (b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein in cells treated with the adipocyte differentiation inhibitor candidate in step (a); And (c) determining the adipocyte differentiation inhibitor candidate as an adipocyte differentiation inhibitor when the amount of expression or activity measured in step (b) is lower than that of the control cells not treated with the adipocyte differentiation inhibitor candidate. It provides a method for screening an adipocyte differentiation inhibitor comprising a.
상기 지방세포 분화 억제제의 스크리닝 방법은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The screening method of the adipocyte differentiation inhibitor may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
본 발명의 용어, "지방세포 분화 억제제 후보 물질"은 통상적인 선정방식에 따라 지방 세포 분화를 억제할 수 있는 가능성을 지닌 것으로 추정되거나 또는 무작위적으로 선정된 개별적인 핵산, 단백질, 기타 추출물 또는 천연물, 또는 화합물 등이 될 수 있고, 구체적으로, 저분자 화합물, 유기합성물질, 천연물질, microRNA, siRNA, shRNA, 항체, 앱타머 등이 될 수 있으나, 이에 제한되지 않는다.As used herein, the term “dipotent differentiation inhibitor candidate” refers to individual nucleic acids, proteins, other extracts or natural products presumed to have the possibility of inhibiting adipocyte differentiation according to a conventional selection method or randomly selected; Or a compound, and the like, and specifically, may be a low molecular compound, an organic synthetic material, a natural material, a microRNA, siRNA, shRNA, an antibody, aptamer, and the like, but is not limited thereto.
본 발명의 용어 “단백질 또는 상기 단백질을 코딩하는 유전자의 발현량 또는 활성의 측정”, 및 “대조군”은 상술한 바와 같다. The terms "measurement of the amount or activity of expression of a protein or gene encoding said protein", and "control" are as described above.
본 발명의 용어 “지방세포 분화 억제제의 스크리닝 방법”은, 지방세포로 분화하는 과정에 CLUH 또는 BMPER의 발현이 관련됨을 확인함으로써, CLUH 또는 BMPER의 활성 및 발현을 지방세포 분화 억제제 후보 물질을 처리하지 않은 대조군 세포와 비교하는 방식으로 고안되었다. 지방세포의 분화를 억제할 수 있는 후보 물질의 부재 하에 세포에서의 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준을 측정하고, 또한, 상기 후보 물질의 존재 하에서 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준을 측정하여 양자를 비교한 후, 상기 후보 물질이 존재할 때의 본 발명의 상기 유전자의 발현 수준 또는 상기 유전자가 코딩하는 단백질의 수준이 상기 후보 물질의 부재 하에서의 수준보다 감소시키는 물질을 지방세포 분화 억제제로 예측할 수 있다.The term “screening method of adipocyte differentiation inhibitor” of the present invention confirms that expression of CLUH or BMPER is involved in adipocyte differentiation, thereby not treating the adipocyte differentiation inhibitor candidates with the activity and expression of CLUH or BMPER. It was designed in a way that compares with control cells. Measuring the expression level of the gene of the present invention or the level of the protein encoded by the gene in the cell in the absence of a candidate substance capable of inhibiting the differentiation of adipocytes, and also in the presence of the candidate substance After comparing the two by measuring the expression level of the gene or the level of the protein encoded by the gene, the expression level of the gene of the present invention when the candidate substance is present or the level of the protein encoded by the gene is determined as the candidate substance. Substances that decrease below levels in the absence of can be predicted as adipocyte differentiation inhibitors.
이러한 스크리닝 방법에 의하여 얻어진 물질은 지방세포 분화 억제제로 사용될 수 있으며, 특히 비만의 예방 또는 치료에 사용될 수 있다.The material obtained by this screening method can be used as an inhibitor of adipocyte differentiation, and especially can be used for the prevention or treatment of obesity.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방 세포 분화 촉진제의 스크리닝용 키트를 제공한다.In still another aspect, the present invention provides a kit for screening an adipocyte differentiation promoter comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 지방 세포 분화 촉진제의 스크리닝용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The kit for screening the adipocyte differentiation promoter may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 지방 세포 분화 촉진제의 스크리닝용 키트를 이용하여, 지방 세포 분화 촉진제 후보 물질로부터 지방 세포 분화 촉진제를 선정할 수 있다.The fat cell differentiation promoter can be selected from the adipocyte candidates for adipocyte differentiation using the kit for screening the adipocyte differentiation promoter of this invention.
본 발명에서 “CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제” 및 “키트”는 상술한 바와 같다.In the present invention, the "agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein" and the "kit" are as described above.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방 세포 분화 억제제의 스크리닝용 키트를 제공한다.In still another aspect, the present invention provides a kit for screening an adipocyte differentiation inhibitor comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 지방 세포 분화 억제제의 스크리닝용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The kit for screening the adipocyte differentiation inhibitor may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 지방 세포 분화 억제제의 스크리닝용 키트를 이용하여, 지방 세포 분화 억제제 후보 물질로부터 지방 세포 분화 억제제를 선정할 수 있다.The kit for screening an adipocyte differentiation inhibitor of the present invention can be used to select an adipocyte differentiation inhibitor from a candidate adipocyte differentiation inhibitor.
본 발명에서 “CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제” 및 “키트”는 상술한 바와 같다.In the present invention, the "agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein" and the "kit" are as described above.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방세포 분화 촉진제의 효능 검정용 키트를 제공한다. In still another aspect, the present invention provides a kit for assaying the efficacy of an adipocyte differentiation promoter comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 지방세포 분화 촉진제의 효능 검정용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The kit for assaying efficacy of the adipocyte differentiation promoter may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명에서 “CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제”, “지방세포 분화 촉진제”, 및 “키트”는 상술한 바와 같다.In the present invention, "agent for measuring expression level of CLUH or BMPER protein or gene encoding the protein", "fat cell differentiation promoter", and "kit" are as described above.
본 발명의 "지방세포 분화 촉진제의 효능 검정용 키트"는 상기 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하고, 지방세포 분화 촉진제가 처리된 CLUH 또는 BMPER을 발현하는 세포에서 CLUH 또는 BMPER 단백질 또는 상기 유전자의 발현 수준을 측정 가능한 키트일 수 있다. 상기 측정된 CLUH 또는 BMPER의 발현수준이 높을수록 효과적인 지방세포 분화 촉진제인 것으로 검정할 수 있다. 이와 같은 효능 검정용 키트는 일반적인 지방세포 분화 과정에서의 지방세포 분화 촉진제의 역가 검증 등에 유효하게 이용될 수 있다."Efficacy assay kit for adipocyte differentiation promoter" of the present invention includes an agent for measuring the expression level of the protein or the gene encoding the protein, in the cells expressing CLUH or BMPER treated adipocyte differentiation promoter It may be a kit capable of measuring the expression level of the CLUH or BMPER protein or the gene. The higher the expression level of CLUH or BMPER measured can be assayed as an effective adipocyte differentiation promoter. Such an efficacy assay kit can be effectively used for verifying the titer of adipocyte differentiation promoter in a general adipocyte differentiation process.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방세포 분화 억제제의 효능 검정용 키트를 제공한다. In still another aspect, the present invention provides a kit for assaying the efficacy of an adipocyte differentiation inhibitor comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 지방세포 분화 억제제의 효능 검정용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The kit for assaying efficacy of the adipocyte differentiation inhibitor may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명에서 “CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제”, “지방세포 분화 억제제”, 및 “키트”는 상술한 바와 같다.In the present invention, "agent for measuring the expression level of CLUH or BMPER protein or gene encoding the protein", "fat cell differentiation inhibitor", and "kit" are as described above.
본 발명의 "지방세포 분화 억제제의 효능 검정용 키트"는 상기 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하고, 지방세포 분화 억제제가 처리된 CLUH 또는 BMPER을 발현하는 세포에서 CLUH 또는 BMPER 단백질 또는 상기 유전자의 발현 수준을 측정 가능한 키트일 수 있다. 상기 측정된 CLUH 또는 BMPER의 발현수준이 낮을수록 효과적인 지방세포 분화 억제제인 것으로 검정할 수 있다. 이와 같은 효능 검정용 키트는 일반적인 지방세포 분화 과정에서의 지방세포 분화 억제제의 역가 검증 등에 유효하게 이용될 수 있다."Efficacy assay kit for adipocyte differentiation inhibitor" of the present invention includes an agent for measuring the expression level of the protein or the gene encoding the protein, in the cells expressing CLUH or BMPER treated adipocyte differentiation inhibitor It may be a kit capable of measuring the expression level of the CLUH or BMPER protein or the gene. The lower the expression level of CLUH or BMPER measured above can be assayed as an effective adipocyte differentiation inhibitor. Such an efficacy assay kit can be effectively used for verifying the titer of adipocyte differentiation inhibitor in general adipocyte differentiation process.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는, 비만 진단을 위한 마커 검출용 조성물을 제공한다.As another aspect, the present invention provides a composition for detecting a marker for diagnosing obesity, comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 비만 진단을 위한 마커 검출용 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The marker detection composition for diagnosing obesity may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
본 발명에서 CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제는 상술한 바와 같다.In the present invention, the agent for measuring the expression level of the CLUH or BMPER protein or the gene encoding the protein is as described above.
본 발명의 용어, “비만 진단을 위한 마커”는 정상인 개체와 비만인 개체에서 유의한 발현량 차이를 나타내는 유기 생체 분자를 의미할 수 있다.As used herein, the term “marker for diagnosing obesity” may refer to an organic biomolecule that exhibits a significant difference in expression in normal individuals and obese individuals.
본 발명의 비만 진단을 위한 마커 검출용 조성물을 이용하여, CLUH 또는 BMPER의 발현 수준과 동등 또는 그 이상의 수준으로, 비만이 아닌 개체 및 비만인 개체에서의 발현 수준이 유의한 차이를 나타내는 비만 진단을 위한 마커를 검출할 수 있다.By using the marker detection composition for diagnosing obesity of the present invention, the level of expression equal to or higher than that of CLUH or BMPER, and for the diagnosis of obesity, the expression level in the non-obese and obese individuals shows a significant difference Markers can be detected.
본 발명은 또 다른 양태로서, 상기 비만 진단을 위한 마커 검출용 조성물을 포함하는, 비만 진단을 위한 마커 검출용 키트를 제공한다.As another aspect, the present invention provides a marker detection kit for diagnosing obesity, comprising a composition for detecting markers for diagnosing obesity.
상기 비만 진단을 위한 마커 검출용 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The marker detection composition for diagnosing obesity may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER protein or gene encoding the protein.
본 발명의 용어, “CLUH 또는 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제”, “비만 진단을 위한 마커”, “비만 진단을 위한 마커 검출용 조성물”, 및 키트는 상술한 바와 같다.As used herein, the term “agent for measuring the expression level of a CLUH or BMPER protein or a gene encoding the protein”, “a marker for diagnosing obesity”, “a composition for detecting a marker for diagnosing obesity”, and a kit are described above. As shown.
본 발명의 비만 진단을 위한 마커 검출용 키트를 이용하여, 대조군 시료에서보다 유의한 발현량 차이를 보이는 비만 진단을 위한 마커를 검출할 수 있다.Using the marker detection kit for diagnosing obesity of the present invention, it is possible to detect a marker for diagnosing obesity, which shows a significant difference in expression level than in a control sample.
본 발명은 또 다른 양태로서, 비만의 예방 또는 치료용 의약의 제조에 있어서, 상기 약학적 조성물의 용도를 제공한다.In another aspect, the present invention provides a use of the pharmaceutical composition in the manufacture of a medicament for preventing or treating obesity.
본 발명은 또 다른 양태로서, CLUH 또는 BMPER 단백질 또는 유전자의 비만 진단 마커 용도를 제공한다.In another aspect, the present invention provides the use of a diagnostic marker for obesity of a CLUH or BMPER protein or gene.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자를 과발현 시키는 제제를 포함하는 지방 세포 분화 촉진용 조성물을 제공한다.As another aspect, the present invention provides a composition for promoting adipocyte differentiation comprising an agent for overexpressing one or more proteins of CLUH and BMPER proteins, or a gene encoding the one or more proteins.
본 발명의 용어, “CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자를 과발현 시키는 제제”는 CLUH, BMPER 또는 CLUH 및 BMPER 모두의 발현량을 증대시켜, 지방세포로의 분화를 촉진할 수 있는 물질이면 어느 것이든 제한이 없으며, 핵산, 단백질, 기타 추출물 또는 천연물, 또는 화합물 등이 될 수 있고, 구체적으로, 저분자 화합물, 유기합성물질, 천연물질 등이 될 수 있으나, 이에 제한되지 않는다. The term of the present invention, “an agent that overexpresses one or more proteins of CLUH and BMPER protein, or a gene encoding the one or more proteins”, increases the expression level of CLUH, BMPER or both CLUH and BMPER, thereby promoting differentiation into adipocytes. Any material that can be promoted is not limited, and may be nucleic acids, proteins, other extracts or natural products, or compounds, and specifically, may be low molecular weight compounds, organic synthetic materials, natural materials, and the like. It doesn't work.
본 발명의 지방 세포 분화 촉진용 조성물은 CLUH 또는 BMPER의 과발현을 통해 지방 세포로의 분화를 촉진할 수 있다.The composition for promoting adipocyte differentiation of the present invention may promote differentiation into adipocytes through overexpression of CLUH or BMPER.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방 세포로의 분화 진단 마커 검출용 조성물을 제공한다.In still another aspect, the present invention provides a composition for detecting a diagnostic marker for differentiation into adipocytes, which comprises an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 지방 세포로의 분화 진단 마커 검출용 조성물은 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The composition for detecting a diagnostic marker for differentiation into adipocytes may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 용어 “CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제”, 및 “마커”는 상술한 바와 같다.The terms "agent for measuring the expression level of one or more proteins of CLUH and BMPER proteins, or genes encoding said one or more proteins", and "markers" are as described above.
본 발명의 용어 “지방 세포로의 분화 진단 마커”는 지방세포의 분화 진행 과정에 따라 유의적인 발현량 차이를 보이는 유기 생체 분자를 의미한다.The term "differentiation diagnostic marker to adipocytes" of the present invention refers to an organic biomolecule showing a significant difference in expression according to the process of differentiation of adipocytes.
본 발명의 지방 세포로의 분화 진단 마커 검출용 조성물은 지방 세포로의 분화 과정에서 CLUH 또는 BMPER과 동등한 수준 또는 그 이상의 수준으로 발현량 차이를 보이는 유기 생체 분자를 검출할 수 있다.The composition for detecting a diagnostic marker for differentiation into adipocytes of the present invention can detect organic biomolecules having a difference in expression level at a level equivalent to or higher than that of CLUH or BMPER during the differentiation into adipocytes.
본 발명은 또 다른 양태로서, CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방 세포로의 분화 진단용 키트를 제공한다.In still another aspect, the present invention provides a kit for diagnosing differentiation into adipocytes, which comprises an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
상기 지방 세포로의 분화 진단용 키트는 CLUH, BMPER, 또는 CLUH 및 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현수준을 측정하는 것일 수 있다. The diagnostic kit for differentiation into adipocytes may be to measure the expression level of CLUH, BMPER, or CLUH and BMPER proteins or genes encoding the proteins.
본 발명의 용어 “CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제”, 및 “키트”는 상술한 바와 같다.The terms "agent for measuring the expression level of one or more proteins of CLUH and BMPER proteins, or genes encoding said one or more proteins", and "kit" are as described above.
본 발명의 지방 세포로의 분화 진단용 키트는 CLUH 또는 BMPER 발현량을 측정함으로써, 지방 세포로의 분화 과정을 측정 및 진단할 수 있다.The diagnostic kit for differentiation into adipocytes of the present invention can measure and diagnose the process of differentiation into adipocytes by measuring the amount of CLUH or BMPER expression.
실시예 1. CLUH (Clustered mitochondrial homolog) 발현과 지방 세포분화의 관계 확인Example 1. Confirmation of the relationship between the clustered mitochondrial homolog (CLUH) expression and adipocyte differentiation
1-1.T3-L1 세포주의 준비1-1.Preparation of T3-L1 Cell Line
3T3-L1은 마우스 배아섬유아세포(mouse embryonic fibroblast) 세포주로서, 대사 질환 및 비만 연구 모델에 주로 사용된다. ATCC에서 구입한 세포주를 BCS(Bovine Calf serum)을 포함한 DMEM(Dulbecco's modified Eagle's medium)에서 배양하여 사용하였다.3T3-L1 is a mouse embryonic fibroblast cell line and is mainly used for metabolic disease and obesity research models. Cell lines purchased from ATCC were used by culturing in DMEM (Dulbecco's modified Eagle's medium) including Bovine Calf serum (BCS).
1-2. 지방세포로의 분화 유도 1-2. Induction of differentiation into adipocytes
35 mm 디쉬에 3T3-L1 0.8 × 105 개의 세포를 씨딩(seeding)하여 5일이 지났을 때 0일차(0 day)로 하였다. 0 일차에는 분화 유도 칵테일(differentiation cocktail, IBMX 0.5 mM, 인슐린 10 ug/mL, 덱사메사손(dexamathson) 1uM)을 태아 소 혈청(Fetal bovine serum, FBS)을 포함한 DMEM(Dulbecco's modified Eagle's medium)에 섞어 3T3-L1 세포의 지방세포로의 분화를 유도하였다. 매 2일마다 인슐린이 들어있는 배지로 1:1 배치 교체를 하였다.3T3-L1 0.8 × 10 5 cells were seeded in a 35 mm dish to make day 0 when 5 days had passed. On day 0, differentiation cocktail (IBMX 0.5 mM, insulin 10 ug / mL, dexamethson 1uM) was mixed with DMEM (Dulbecco's modified Eagle's medium) containing Fetal bovine serum (FBS). Differentiation of 3T3-L1 cells into adipocytes was induced. Every 2 days a 1: 1 batch change was made with medium containing insulin.
1-3. RNA 분리 및 RT-PCR1-3. RNA Isolation and RT-PCR
Ribospin columns(GeneAll, 대한민국)을 이용하여 RNA를 추출하였고, RNA 농도는 ND-1000 분광 광도계 (spectrophotometer, NanoDrop Technologies, Inc. Wilmington, DE, USA)를 이용하여 측정하였다. 또한, iScript™ cDNA 합성 키트(Biorad, USA)를 이용하여 cDNA(complementary DNA)를 합성하였고, Maxime PCR PreMix 키트(i-StarTaq; Intron Biotechnology)를 이용하여 RT-PCR(Reverse transcriptase-polymerase chain reaction)을 수행하였다. RT-PCR에 사용된 프라이머는 하기와 같다.RNA was extracted using Ribospin columns (GeneAll, South Korea), and RNA concentration was measured using an ND-1000 spectrophotometer (spectrophotometer, NanoDrop Technologies, Inc. Wilmington, DE, USA). Complementary DNA (cDNA) was also synthesized using the iScript ™ cDNA Synthesis Kit (Biorad, USA), and reverse transcriptase-polymerase chain reaction (RT-PCR) using Maxime PCR PreMix kit (i-StarTaq; Intron Biotechnology). Was performed. Primers used for RT-PCR are as follows.
CLUH ForwardCLUH Forward AGGGGTTCGATTTCCTGAGTAGGGGTTCGATTTCCTGAGT 서열번호 1SEQ ID NO: 1
CLUH ReverseCLUH Reverse CCAGGTATCGCATGTTGATGCCAGGTATCGCATGTTGATG 서열번호 2SEQ ID NO: 2
1-4. Oil Red O 염색1-4. Oil Red O Dyeing
3.7 % 포름알데하이드로 세포를 고정시킨 후, 60% 아이소프로판올로 5분간 배양하였다. 그 후, 세포 흡입(suction)을 하고 디쉬를 완전히 건조시켰다. Oil Red와 물을 3:2로 희석하여 세포를 염색시키고 1시간이 경과하면 물로 2-3번 세척하였다.The cells were fixed with 3.7% formaldehyde and then incubated with 60% isopropanol for 5 minutes. Thereafter, cell suction was performed and the dish was completely dried. Oil Red and water were diluted 3: 2 and stained with cells. After 1 hour, the cells were washed 2-3 times with water.
1-5. 지방 생성 과정에서 CLUH의 발현 증가의 확인1-5. Confirmation of increased expression of CLUH during fat production
상술한 대로 3T3-L1 세포주를 이용하여 지방세포로의 분화를 유도하였고, 지방세포로의 분화가 진행되는 과정에서 본 발명의 CLUH 유전자의 발현이 증가되는 것을 확인하였다. 도 1의 A에 개시된 것처럼, 분화 2일차부터 CLUH의 발현이 증가되는 것을 확인하였다. As described above, the 3T3-L1 cell line was used to induce differentiation into adipocytes, and it was confirmed that expression of the CLUH gene of the present invention was increased in the course of differentiation into adipocytes. As disclosed in A of FIG. 1, it was confirmed that the expression of CLUH was increased from the second day of differentiation.
또한, 지방세포로의 분화 여부를 알 수 있는 양성 마커인 PPAR 감마, SRE BP1-C, C/EBPα, 및 FABP4 의 발현 역시 CLUH과 마찬가지로 증가하는 것을 확인하였다. In addition, it was confirmed that the expression of PPAR gamma, SRE BP1-C, C / EBPa, and FABP4, which are positive markers for differentiation into adipocytes, also increased as in CLUH.
더 나아가, 도 1의 B에 나타난 것처럼, Oil Red O 염색을 통해 지방세포로의 분화가 활발히 일어난 것을 확인하였다. Furthermore, as shown in FIG. 1B, it was confirmed that differentiation into adipocytes was actively performed through Oil Red O staining.
상기와 같은 실험결과로부터, CLUH이 지방세포로 분화하는 과정에 관여하는 것을 확인하였고, 더 나아가, 상기 CLUH을 억제함으로써 지방생성을 억제할 수 있는지 여부를 확인하고자 하였다.From the above experimental results, it was confirmed that the CLUH is involved in the process of differentiating into adipocytes, and furthermore, to determine whether the fat production can be inhibited by inhibiting the CLUH.
실시예 2. CLUH (Clustered mitochondrial homolog) 의 억제와 지방 축적과의 관계 확인Example 2 Confirmation of the relationship between inhibition of CLUH (Clustered mitochondrial homolog) and fat accumulation
2-1. siRNA의 준비2-1. siRNA preparation
CLUH의 억제 효과를 확인하고자, siRNA를 제작하였다. CLUH의 siRNA인, siCLUH#1(서열번호 3) 및 siCLUH#3(서열번호 4)는 주문 제작하였고, 대조군 siRNA(si-Con)는 구입하여 사용하였다 (Mbiotech, 대한민국, 서울). In order to confirm the inhibitory effect of CLUH, siRNA was produced. SiCLUH siRNA, siCLUH # 1 (SEQ ID NO: 3) and siCLUH # 3 (SEQ ID NO: 4), were custom-made and control siRNA (si-Con) was purchased and used (Mbiotech, South Korea, Seoul).
siCLUH#1 siCLUH # 1 GCTTCAATCCTGACATCTTGCTTCAATCCTGACATCTT 서열번호 3SEQ ID NO: 3
siCLUH#3 siCLUH # 3 GGGCATCATTGGCAATGATGGGCATCATTGGCAATGAT 서열번호 4SEQ ID NO: 4
si-Consi-Con CCUCGUGCCGUUCCAUCAGGUAGUUCCUCGUGCCGUUCCAUCAGGUAGUU 서열번호 19SEQ ID NO: 19
2-2. siRNA를 이용한 CLUH 발현의 억제2-2. Inhibition of CLUH Expression with siRNA
상술한 것과 동일한 세포 0.8 × 105 개를 35 mm 디쉬에 씨딩하여 4일 경과 후, Lipofectamine RNAi MAX 시약(Invitrogen, CA) 및 Opti-MEM (Invitrogen, CA) 을 이용하여 100 nM siRNA의 형질주입(transfection)을 수행하고, 그 다음날부터 분화 유도 칵테일(differentiation cocktail, IBMX 0.5 mM, 인슐린 10 ug/mL, 덱사메사손(dexamathson) 1uM을 이용하여 3T3-L1 세포를 지방분화세포로 분화하도록 유도 하였다. 매 2일마다 인슐린 처리를 하였다. Four days after seeding the same 0.8 × 10 5 cells into a 35 mm dish, transfection of 100 nM siRNA using Lipofectamine RNAi MAX reagent (Invitrogen, CA) and Opti-MEM (Invitrogen, CA) was performed. transfection) was performed, and from the next day, 3T3-L1 cells were induced to differentiate into adipocytes using a differentiation cocktail (IBMX 0.5 mM, insulin 10 ug / mL, dexamethasone) 1 uM. Insulin treatment every 2 days.
2-3. CLUH의 발현 억제에 의한 지방세포로의 분화 억제 및 지방 축적 감소2-3. Inhibition of differentiation into adipocytes and reduction of fat accumulation by inhibition of CLUH expression
siRNA를 이용하여 CLUH의 발현이 억제되었을 때, 지방축적에 미치는 영향을 확인하였다. When the expression of CLUH was suppressed by siRNA, the effect on fat accumulation was confirmed.
siCLUH#1 및 siCLUH#3에 의하여 유전자발현이 억제될 때 Oil red O 염색이 크게 감소하였으며, 지방 분화에 대한 양성마커인 PPAR 감마의 발현 역시 감소하는 것을 확인하였다. 특히, 두 siRNA에 의한 CLUH의 억제 모두 지방세포로의 분화를 억제하고 지방 축적을 감소시키는 것을 확인하여, CLUH에 의한 억제로 지방 세포로의 분화를 억제하고 지방 축적을 감소시킬 수 있음을 확인하였다.When gene expression was inhibited by siCLUH # 1 and siCLUH # 3, Oil red O staining was greatly reduced, and the expression of PPAR gamma, a positive marker for adipose differentiation, was also reduced. In particular, it was confirmed that the inhibition of CLUH by both siRNAs inhibited the differentiation of adipocytes and reduced fat accumulation, and it was confirmed that the inhibition by CLUH could inhibit the differentiation of adipocytes and reduce fat accumulation.
또한, 미토콘드리아 관련 유전자인 UCP-1, Tfam의 발현도 감소하는 것을 확인하였다 (도 2의 A 및 B). In addition, it was confirmed that the expression of mitochondrial related genes UCP-1, Tfam also decreased (A and B of Figure 2).
상기와 같은 실시예로부터, CLUH 유전자의 발현을 억제하여 비만을 예방 또는 치료하거나, 또는 이의 발현 수준을 측정하여 비만 치료제를 스크리닝 할 수 있음을 확인하였다.From the above examples, it was confirmed that the anti-obesity agent can be screened by inhibiting the expression of the CLUH gene to prevent or treat obesity, or by measuring its expression level.
또한, 본 발명자들은, BMPER (BMP binding endothelial regulator)의 발현이 지방 세포로의 분화 및 지방 축적에 미치는 영향을 확인하고자, 하기와 같은 실험을 수행하였다.In addition, the inventors performed the following experiments to determine the effect of BMPER (BMP binding endothelial regulator) on the differentiation and fat accumulation of adipocytes.
실시예 3. BMPER (BMP binding endothelial regulator) 발현과 지방 세포분화의 관계 확인Example 3. Confirmation of the relationship between BMPER (BMP binding endothelial regulator) expression and adipocyte differentiation
3-1.T3-L1 세포주의 준비3-1.Preparation of T3-L1 Cell Line
3T3-L1은 마우스 배아섬유아세포(mouse embryonic fibroblast) 세포주로서, 대사 질환 및 비만 연구 모델에 주로 사용된다. ATCC에서 구입한 세포주를 BCS(Bovine Calf serum)을 포함한 DMEM(Dulbecco's modified Eagle's medium)에서 배양하여 사용하였다.3T3-L1 is a mouse embryonic fibroblast cell line and is mainly used for metabolic disease and obesity research models. Cell lines purchased from ATCC were used by culturing in DMEM (Dulbecco's modified Eagle's medium) including Bovine Calf serum (BCS).
3-2. 지방세포로의 분화 유도 3-2. Induction of differentiation into adipocytes
35 mm 디쉬에 3T3-L1 0.8 × 105 개의 세포를 씨딩(seeding)하여 5일이 지났을 때 0일차(0 day)로 하였다. 0 일차에는 분화 유도 칵테일(differentiation cocktail, IBMX 0.5 mM, 인슐린 10 ug/mL, 덱사메사손(dexamathson) 1uM)을 태아 소 혈청(Fetal bovine serum, FBS)을 포함한 DMEM(Dulbecco's modified Eagle's medium)에 섞어 3T3-L1 세포의 지방세포로의 분화를 유도하였다. 매 2일마다 인슐린이 들어있는 배지로 1:1 배치 교체를 하였다.3T3-L1 0.8 × 10 5 cells were seeded in a 35 mm dish to make day 0 when 5 days had passed. On day 0, differentiation cocktail (IBMX 0.5 mM, insulin 10 ug / mL, dexamethson 1uM) was mixed with DMEM (Dulbecco's modified Eagle's medium) containing Fetal bovine serum (FBS). Differentiation of 3T3-L1 cells into adipocytes was induced. Every 2 days a 1: 1 batch change was made with medium containing insulin.
3-3. RNA 분리 및 RT-PCR3-3. RNA Isolation and RT-PCR
Ribospin columns(GeneAll, 대한민국)을 이용하여 RNA를 추출하였고, RNA 농도는 ND-1000 분광 광도계 (spectrophotometer, NanoDrop Technologies, Inc. Wilmington, DE, USA)를 이용하여 측정하였다. 또한, iScript™ cDNA 합성 키트(Biorad, USA)를 이용하여 cDNA(complementary DNA)를 합성하였고, Maxime PCR PreMix 키트(i-StarTaq; Intron Biotechnology)를 이용하여 RT-PCR(Reverse transcriptase-polymerase chain reaction)을 수행하였다. RT-PCR에 사용된 프라이머는 하기와 같다.RNA was extracted using Ribospin columns (GeneAll, South Korea), and RNA concentration was measured using an ND-1000 spectrophotometer (spectrophotometer, NanoDrop Technologies, Inc. Wilmington, DE, USA). Complementary DNA (cDNA) was also synthesized using the iScript ™ cDNA Synthesis Kit (Biorad, USA), and reverse transcriptase-polymerase chain reaction (RT-PCR) using Maxime PCR PreMix kit (i-StarTaq; Intron Biotechnology). Was performed. Primers used for RT-PCR are as follows.
BMPER ForwardBMPER Forward attctctcttgtccccagcaattctctcttgtccccagca 서열번호 6SEQ ID NO: 6
BMPER ReverseBMPER Reverse caaatgaggctccattgtcacaaatgaggctccattgtca 서열번호 7SEQ ID NO: 7
3-4. Oil Red O 염색3-4. Oil Red O Dyeing
3.7 % 포름알데하이드로 세포를 고정시킨 후, 60% 아이소프로판올로 5분간 배양하였다. 그 후, 세포 흡입(suction)을 하고 디쉬를 완전히 건조시켰다. Oil Red와 물을 3:2로 희석하여 세포를 염색시키고 1시간이 경과하면 물로 2-3번 세척하였다.The cells were fixed with 3.7% formaldehyde and then incubated with 60% isopropanol for 5 minutes. Thereafter, cell suction was performed and the dish was completely dried. Oil Red and water were diluted 3: 2 and stained with cells. After 1 hour, the cells were washed 2-3 times with water.
3-5. 지방 생성 과정에서 BMPER의 발현 증가의 확인3-5. Confirmation of increased expression of BMPER during fat production
상술한 대로 3T3-L1 세포주를 이용하여 지방세포로의 분화를 유도하였고, 지방세포로의 분화가 진행되는 과정에서 본 발명의 BMPER 유전자의 발현이 증가되는 것을 확인하였다. 도 3의 A에 개시된 것처럼, 분화 2일차부터 BMPER의 발현이 증가되는 것을 확인하였다. As described above, the 3T3-L1 cell line was used to induce differentiation into adipocytes, and it was confirmed that expression of the BMPER gene of the present invention was increased in the course of differentiation into adipocytes. As disclosed in FIG. 3A, it was confirmed that the expression of BMPER was increased from the second day of differentiation.
또한, 지방세포로의 분화 여부를 알 수 있는 양성 마커인 PPAR 감마, SRE BP1-C, C/EBPα, 및 FABP4 의 발현 역시 BMPER과 마찬가지로 증가하는 것을 확인하였다. In addition, it was confirmed that the expression of PPAR gamma, SRE BP1-C, C / EBPa, and FABP4, which are positive markers for differentiation into adipocytes, also increased as in BMPER.
더 나아가, 도 3의 B에 나타난 것처럼, Oil Red O 염색을 통해 지방세포로의 분화가 활발히 일어난 것을 확인하였다. Furthermore, as shown in B of FIG. 3, it was confirmed that differentiation into adipocytes was actively performed through Oil Red O staining.
상기와 같은 실험결과로부터, BMPER이 지방세포로 분화하는 과정에 관여하는 것을 확인하였고, 더 나아가, 상기 BMPER을 억제함으로써 지방생성을 억제할 수 있는지 여부를 확인하고자 하였다.From the above experimental results, it was confirmed that BMPER is involved in the process of differentiating into adipocytes, and furthermore, to determine whether or not it can suppress the production of fat by inhibiting the BMPER.
실시예 4. BMPER (BMP binding endothelial regulator) 의 억제와 지방 축적과의 관계 확인Example 4. Confirmation of the relationship between the inhibition of BMPER (BMP binding endothelial regulator) and fat accumulation
4-1. siRNA의 준비4-1. siRNA preparation
BMPER의 억제 효과를 확인하고자, siRNA를 제작하였다. BMPER의 siRNA인, siBMPER#1(서열번호 8) 및 siBMPER#3(서열번호 9)는 주문 제작하였고, 대조군 siRNA(si-Con, 서열번호 19)는 구입하여 사용하였다 (Mbiotech, 대한민국, 서울). In order to confirm the inhibitory effect of BMPER, siRNA was produced. SiBMPER # 1 (SEQ ID NO: 8) and siBMPER # 3 (SEQ ID NO: 9), siRNAs of BMPER, were made to order and control siRNA (si-Con, SEQ ID NO: 19) was purchased and used (Mbiotech, South Korea, Seoul). .
siBMPER#1 siBMPER # 1 GCATAATGTGTGTGTGTTTGCATAATGTGTGTGTGTTT 서열번호 8SEQ ID NO: 8
siBMPER#3 siBMPER # 3 GCACAGTATGCACTTGCAAGCACAGTATGCACTTGCAA 서열번호 9SEQ ID NO: 9
4-2. siRNA를 이용한 BMPER 발현의 억제4-2. Inhibition of BMPER Expression with siRNA
상술한 것과 동일한 세포 0.8 × 105 개를 35 mm 디쉬에 씨딩하여 4일 경과 후, Lipofectamine RNAi MAX 시약(Invitrogen, CA) 및 Opti-MEM (Invitrogen, CA) 을 이용하여 100 nM siRNA의 형질주입(transfection)을 수행하고, 그 다음날부터 분화 유도 칵테일(differentiation cocktail, IBMX 0.5 mM, 인슐린 10 ug/mL, 덱사메사손(dexamathson) 1uM)을 이용하여 3T3-L1 세포를 지방분화세포로 분화하도록 유도 하였다. 매 2일마다 인슐린 처리를 하였다. Four days after seeding the same 0.8 × 10 5 cells into a 35 mm dish, transfection of 100 nM siRNA using Lipofectamine RNAi MAX reagent (Invitrogen, CA) and Opti-MEM (Invitrogen, CA) was performed. transfection) and the following day was induced to differentiate 3T3-L1 cells into adipocytes using a differentiation cocktail (IBMX 0.5 mM, insulin 10 ug / mL, dexamethasone (1uM)). . Insulin treatment every 2 days.
4-3. BMPER의 발현 억제에 의한 지방세포로의 분화 억제 및 지방 축적 감소4-3. Inhibition of differentiation into adipocytes and reduction of fat accumulation by inhibition of BMPER expression
siRNA를 이용하여 BMPER의 발현이 억제되었을 때, 지방축적에 미치는 영향을 확인하였다. When the expression of BMPER was suppressed using siRNA, the effect on fat accumulation was confirmed.
BMPER의 siRNA인 siBMPER#1 및 siBMPER#3, 대조군 siRNA인 si-Con을 처리한 3T3-L1 세포의 분화 과정에서 BMPER의 유전자 발현을 RT-PCR로 측정하였다. 그 결과, 분화 3일차에 BMPER의 발현이 억제되며, 분화의 양성 마커인 PPAR gamma의 발현도 감소되는 것을 확인하였다. 또한, BMPER의 하위인자(down stream molecule)인 Id-1의 발현도 감소하는 것을 확인하였다 (도 4의 A).Gene expression of BMPER was measured by RT-PCR during differentiation of 3T3-L1 cells treated with siBMPER # 1 and siBMPER # 3, si-Con, si-Con, siRNA of BMPER. As a result, it was confirmed that the expression of BMPER was inhibited on the third day of differentiation, and the expression of PPAR gamma, a positive marker of differentiation, was also reduced. In addition, it was confirmed that the expression of Id-1, a downstream molecule of BMPER, was also reduced (FIG. 4A).
한편, 분화 유도 6일 차에 Oil Red O 염색을 통해 확인한 결과, 상기 세포에서 지방 축적이 현저히 감소한 사실도 확인하였다 (도 4의 B).On the other hand, as a result of oil red O staining on the 6th day of induction of differentiation, it was also confirmed that the fat accumulation in the cells was significantly reduced (Fig. 4B).
상기와 같은 실시예로부터, BMPER 유전자의 발현을 억제하여 비만을 예방 또는 치료하거나, 또는 이의 발현 수준을 측정하여 비만 치료제를 스크리닝 할 수 있음을 확인하였다.From the above examples, it was confirmed that the anti-obesity agent can be screened by inhibiting the expression of the BMPER gene to prevent or treat obesity, or by measuring its expression level.
실시예 5. 사람 세포의 지방 축적 및 지방세포로의 분화 과정에서의 CLUH 및 BMPER 발현 증가Example 5 Increased CLUH and BMPER Expression During Adipogenesis and Differentiation of Human Cells
본 발명자들은, 상기와 같은 실시예로부터 CLUH 및 BMPER이 지방 축적 및 지방세포로의 분화에 관여함을 발견하였으며, 인간세포에서도 동일한 기능을 수행하는지 여부를 확인하고자 하였다.The present inventors have found that CLUH and BMPER are involved in fat accumulation and differentiation into adipocytes from the above examples, and tried to determine whether human cells perform the same function.
이에, 상기 실시예에서 사용된 3T3-L1 세포를 비롯한, 다양한 세포(3T3L1, C3H10T1/2, Messenchymal stem cell)에 지방 분화를 유도하여 CLUH 및 BMPER의 발현을 Real time PCR을 통해 확인하였으며, 이에 사용된 CLUH 및 BMPER의 프라이머 서열은 하기와 같다.Thus, the expression of CLUH and BMPER was confirmed by real time PCR by inducing adipose differentiation in various cells (3T3L1, C3H10T1 / 2, Messenchymal stem cells), including 3T3-L1 cells used in the above examples. Primer sequences of CLUH and BMPER were as follows.
hCLUH ForwardhCLUH Forward 5'-GCATCCTCTTCATTCCTCTCAG-3'5'-GCATCCTCTTCATTCCTCTCAG-3 ' 서열번호 11SEQ ID NO: 11
hCLUH ReversehCLUH Reverse 5'-CGGCTCTATCCCTGTTTCTG-3'5'-CGGCTCTATCCCTGTTTCTG-3 ' 서열번호 12SEQ ID NO: 12
hBMPER ForwardhBMPER Forward 5'-TGTTTGAGGGTGTGCAGTATC-3'5'-TGTTTGAGGGTGTGCAGTATC-3 ' 서열번호 13SEQ ID NO: 13
hBMPER ReversehBMPER Reverse 5'-GGGTATGTGACTAAGGTGCTG-3'5'-GGGTATGTGACTAAGGTGCTG-3 ' 서열번호 14SEQ ID NO: 14
상기 실시예와 마찬가지로, Real time PCR은 iQ SYBR Green supermix (Bio-Rad)을 이용하여 증폭하였다. Reference 유전자로는 mouse 유래 세포는 RPL13A 유전자, human 유래 세포는 β-actin 유전자를 사용하였다. primer 서열은 다음과 같다. mRPL13A (Forward 5'-CCTGCTGCTCTCAAGGTTGTT-3', 서열번호 15; Reverse 5'-CGATAGTGCATCTTGGCCTTT-3', 서열번호 16), β-actin (Forward 5'-GCACCACACCTTCTACAATGA-3', 서열번호 17; Reverse 5'-TAGCACAGCCTGGATAGCAAC-3', 서열번호 18).Like the above example, real time PCR was amplified using iQ SYBR Green supermix (Bio-Rad). As the reference gene, mouse-derived cells were RPL13A gene and human-derived cells were β-actin gene. The primer sequence is as follows. mRPL13A (Forward 5'-CCTGCTGCTCTCAAGGTTGTT-3 ', SEQ ID NO: 15; Reverse 5'-CGATAGTGCATCTTGGCCTTT-3', SEQ ID NO: 16), β-actin (Forward 5'-GCACCACACCTTCTACAATGA-3 ', SEQ ID NO: 17; Reverse 5'- TAGCACAGCCTGGATAGCAAC-3 ', SEQ ID NO: 18).
그 결과, 생쥐의 지방 전구세포 (3T3L1, C3H10T1/2) 및 인간의 중간엽줄기세포 (Messenchymal stem cell, hMSC) 에서 CLUH 및 BMPER의 발현이 증대되는 것을 확인하였다 (도 5 및 6).As a result, it was confirmed that the expression of CLUH and BMPER is increased in mouse fat progenitor cells (3T3L1, C3H10T1 / 2) and human mesenchymal stem cells (hMSC) (FIGS. 5 and 6).
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art will appreciate that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the embodiments described above are to be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.

Claims (23)

  1. CLUH (Clustered mitochondrial homolog) 및 BMPER (BMP binding endothelial regulator) 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 비만 치료 또는 예방용 약학 조성물.A pharmaceutical composition for treating or preventing obesity, comprising an agent that inhibits the expression or activity of at least one of CLUH (Clustered mitochondrial homolog) and BMPER (BMP binding endothelial regulator) protein, or a gene encoding the at least one protein.
  2. 제1항에 있어서, 상기 약학 조성물은 CLUH 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises an agent that inhibits the expression or activity of a CLUH protein or a gene encoding the protein.
  3. 제1항에 있어서, 상기 약학 조성물은 BMPER 단백질 또는 상기 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 것인, 약학 조성물.The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises an agent that inhibits the expression or activity of a BMPER protein or a gene encoding the protein.
  4. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 수준을 측정하는 제제를 포함하는, 비만 진단용 조성물.Comprising an agent for measuring the expression level of at least one of the CLUH and BMPER protein, or the gene encoding the at least one protein, composition for diagnosing obesity.
  5. 제4항의 비만 진단용 조성물을 포함하는, 비만 진단용 키트.Claim 4 diagnostic kit for obesity, comprising the diagnostic composition for obesity.
  6. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현 또는 활성을 억제하는 제제를 포함하는 지방 세포 분화 억제용 조성물.Composition for inhibiting adipocyte differentiation comprising an agent for inhibiting the expression or activity of at least one of the CLUH and BMPER protein, or the gene encoding the at least one protein.
  7. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 단계를 포함하는 비만의 진단 방법.A method of diagnosing obesity comprising measuring the expression level of one or more proteins of the CLUH and BMPER proteins, or a gene encoding the one or more proteins.
  8. (a) 비만 치료제 후보 물질을 CLUH 또는 BMPER 유전자가 발현되는 세포에 처리하는 단계;(a) treating the obese drug candidate with cells expressing the CLUH or BMPER gene;
    (b) 상기 (a) 단계에서 비만 치료제 후보 물질을 처리한 세포에서 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계; 및(b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein, in cells treated with the anti-obesity agent candidate in step (a); And
    (c) 상기 (b) 단계에서 측정한 발현량 또는 활성이 비만 치료제 후보 물질을 처리하지 않은 대조군 세포보다 감소하는 경우, 해당 비만 치료제 후보 물질을 비만 치료제로 판단하는 단계를 포함하는, 비만 치료제의 스크리닝 방법.(c) when the expression or activity measured in step (b) is reduced than control cells that have not been treated with an obesity drug candidate, determining the obesity drug candidate as an anti-obesity agent, Screening method.
  9. 제8항에 있어서, 상기 발현량 또는 활성을 측정하는 단계는 상기 CLUH 또는 BMPER 단백질 또는 상기 유전자의 mRNA의 발현수준을 측정하는 것인, 비만 치료제의 스크리닝 방법.The method of claim 8, wherein measuring the expression level or activity is measuring the expression level of the CLUH or BMPER protein or mRNA of the gene.
  10. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 비만 치료제의 스크리닝용 키트.A kit for screening a therapeutic agent for obesity, comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  11. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 비만 치료제의 효능 검정용 키트.A kit for assaying efficacy of an obesity agent comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  12. (a) 지방세포 분화 촉진제 후보 물질을 CLUH 또는 BMPER 유전자가 발현되는 세포에 처리하는 단계;(a) treating an adipocyte differentiation candidate candidate to a cell expressing a CLUH or BMPER gene;
    (b) 상기 (a) 단계에서 지방세포 분화 촉진제 후보 물질을 처리한 세포에서 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계; 및(b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein in cells treated with the adipocyte differentiation promoter candidate in step (a); And
    (c) 상기 (b) 단계에서 측정한 발현량 또는 활성이 지방세포 분화 촉진제 후보 물질을 처리하지 않은 대조군 세포보다 증가하는 경우, 해당 지방세포 분화 촉진제 후보 물질을 지방세포 분화 촉진제로 판단하는 단계를 포함하는, 지방세포 분화 촉진제의 스크리닝 방법.(c) determining the adipocyte differentiation candidate as an adipocyte differentiation promoter when the amount of expression or activity measured in step (b) is greater than that of the control cells not treated with the adipocyte differentiation candidate. A method for screening an adipocyte differentiation promoter, comprising.
  13. (a) 지방세포 분화 억제제 후보 물질을 CLUH 또는 BMPER 유전자가 발현되는 세포에 처리하는 단계;(a) treating the adipocyte differentiation inhibitor candidate with a cell expressing the CLUH or BMPER gene;
    (b) 상기 (a) 단계에서 지방세포 분화 억제제 후보 물질을 처리한 세포에서 CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현량 또는 활성을 측정하는 단계; 및(b) measuring the expression level or activity of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein in cells treated with the adipocyte differentiation inhibitor candidate in step (a); And
    (c) 상기 (b) 단계에서 측정한 발현량 또는 활성이 지방세포 분화 억제제 후보 물질을 처리하지 않은 대조군 세포보다 감소하는 경우, 해당 지방세포 분화 억제제 후보 물질을 지방세포 분화 억제제로 판단하는 단계를 포함하는, 지방세포 분화 억제제의 스크리닝 방법.(c) determining the adipocyte differentiation inhibitor candidate as an adipocyte differentiation inhibitor when the amount of expression or activity measured in step (b) is lower than that of control cells not treated with the adipocyte differentiation inhibitor candidate. A method for screening an adipocyte differentiation inhibitor, comprising.
  14. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방세포 분화 촉진제의 스크리닝용 키트.Kit for screening adipocyte differentiation promoter comprising an agent for measuring the expression level of at least one of the CLUH and BMPER protein, or the gene encoding the at least one protein.
  15. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방세포 분화 억제제의 스크리닝용 키트.A kit for screening adipocyte differentiation inhibitors comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  16. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방세포 분화 촉진제의 효능 검정용 키트.An kit for assaying the efficacy of an adipocyte differentiation promoter comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  17. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방세포 분화 억제제의 효능 검정용 키트.An kit for assaying efficacy of an adipocyte differentiation inhibitor comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding at least one protein.
  18. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는, 비만 진단을 위한 마커 검출용 조성물.A composition for detecting a marker for diagnosing obesity, comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  19. 제18항의 조성물을 포함하는 비만 진단을 위한 마커 검출용 키트.Marker detection kit for the diagnosis of obesity comprising the composition of claim 18.
  20. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자를 과발현 시키는 제제를 포함하는 지방 세포 분화 촉진용 조성물.Fatty cell differentiation promoting composition comprising at least one protein of CLUH and BMPER protein, or an agent that overexpresses the gene encoding the at least one protein.
  21. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방 세포로의 분화 진단 마커 검출용 조성물.A composition for detecting a diagnostic marker for differentiation into adipocytes, comprising an agent for measuring the expression level of at least one of CLUH and BMPER proteins, or a gene encoding the at least one protein.
  22. CLUH 및 BMPER 단백질 중 하나 이상의 단백질, 또는 상기 하나 이상의 단백질을 코딩하는 유전자의 발현수준을 측정하는 제제를 포함하는 지방 세포로의 분화 진단용 키트.Kit for diagnosing differentiation into adipocytes comprising an agent for measuring the expression level of at least one of the CLUH and BMPER protein, or a gene encoding the at least one protein.
  23. 제1항 내지 제3항 중 어느 한 항의 비만 치료 또는 예방용 약학 조성물을 비만 또는 비만의 위험이 있는 개체에 투여하는 단계를 포함하는, 비만의 예방 또는 치료 방법.A method for preventing or treating obesity, comprising administering the pharmaceutical composition for treating or preventing obesity, according to claim 1, to an individual at risk of obesity or obesity.
PCT/KR2016/009118 2015-08-18 2016-08-18 Pharmaceutical composition for treating or preventing obesity WO2017030394A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2015-0115874 2015-08-18
KR10-2015-0115875 2015-08-18
KR20150115874 2015-08-18
KR20150115875 2015-08-18

Publications (1)

Publication Number Publication Date
WO2017030394A1 true WO2017030394A1 (en) 2017-02-23

Family

ID=58052109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/009118 WO2017030394A1 (en) 2015-08-18 2016-08-18 Pharmaceutical composition for treating or preventing obesity

Country Status (2)

Country Link
KR (1) KR101895973B1 (en)
WO (1) WO2017030394A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008281A1 (en) * 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
KR20140125553A (en) * 2013-04-19 2014-10-29 경북대학교 산학협력단 Composition for diagnosing obesity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090001098A (en) * 2007-06-29 2009-01-08 단국대학교 산학협력단 Development of a dna chip for screening and activity assessment of medicinal or food materials having anti-obesity activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008281A1 (en) * 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
KR20140125553A (en) * 2013-04-19 2014-10-29 경북대학교 산학협력단 Composition for diagnosing obesity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAO ET AL.: "CLUH Regulates Mitochondrial Biogenesis by Binding mRNAs of Nuclear-encoded Mitochondrial Proteins", THE JOURNAL OF CELL BIOLOGY, vol. 207, no. 2, 2014, pages 213 - 223, XP055365316 *
HELBING ET AL.: "Inhibition of BMP Activity Protects Epithelial Barrier Function in Lung Injury", THE JOURNAL OF PATHOLOGY, vol. 231, 2013, pages 105 - 116, XP055365320 *
PAUW, DE ET AL.: "Mitochondrial (dys) Function in Adipocyte (de) Differentiation and Systemic Metabolic Alterations", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 175, no. 3, 2009, pages 927 - 939, XP055365318 *

Also Published As

Publication number Publication date
KR20170022924A (en) 2017-03-02
KR101895973B1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
WO2019182371A1 (en) Composition for diagnosis of degenerative neurological diseases
WO2011071232A1 (en) Method for diagnosis/prognosis of cancers using an epigenetic marker consisting of a specific single cpg site in ttp promoter and treatment of cancers by regulating its epigenetic status
WO2017030395A1 (en) Pharmaceutical composition for treating or preventing obesity
WO2011081465A9 (en) Pharmaceutical composition for suppression of vascularization
WO2017018735A1 (en) Biomarker for determining aging, determining obesity, and diagnosing cancer and diagnosing kit using same
WO2019225923A1 (en) Composition for diagnosing diseases
WO2017030394A1 (en) Pharmaceutical composition for treating or preventing obesity
WO2013100273A1 (en) Radiation exposure diagnostic marker igfbp-5, composition for radiation exposure diagnosis by measuring the expression level of the marker, radiation exposure diagnostic kit comprising the composition, and method for diagnosing radiation exposure using the marker
WO2021002735A1 (en) Cell surface antigen of t cell and various uses thereof
WO2019235876A1 (en) Pharmaceutical composition comprising expression or activity inhibitor of c-src for preventing or treating synucleinopathy
WO2011118994A2 (en) Nlk as a marker for diagnosis of liver cancer and as a therapeutic agent thereof
WO2015046783A1 (en) Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising hrp-3 inhibitor
WO2022169279A1 (en) Composition for prevention or treatment of kidney disease
WO2010137770A1 (en) Novel gpcr protein and use of same
WO2013133472A1 (en) Activating transcription factor 3 (atf3) for toxicity prediction and as therapeutic target
WO2021251656A1 (en) Technique for diagnosing stress by using exosome-derived mirna
WO2011090283A2 (en) Composition containing inhibitors of the expression or activity of sh3rf2 for preventing or treating cancer
WO2020130467A2 (en) Pharmaceutical composition for prevention or treatment of cd8+ memory t cell-mediated disease
WO2014157965A1 (en) Composition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient
WO2011155643A1 (en) Phosphatidylinositol 3-kinases activity regulator including the fifth zinc finger domain of fog2
WO2018012889A1 (en) Composition including itac inhibitor
WO2018088826A2 (en) Composition for diagnosing colorectal cancer metastasis or predicting prognosis and use thereof
WO2009145488A2 (en) Xbp1(s) protein acting as an adipocyte differentiation marker having a facility to regulate differentiation into adipocytes, and an application therefor
WO2023090901A1 (en) Method for selecting marker of cellular senescence using machine learning, biomarker for cellular senescence, and method for screening senolytic agent using same
WO2015126033A1 (en) Composition for controlling stem cell pluripotency, containing lin28a methylation inhibitor, and method for screening for lin28a methylation inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16837336

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16837336

Country of ref document: EP

Kind code of ref document: A1